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CHAPTER 1 
 
PHYSIOLOGY INTRODUCTION 
 
Introductory Comments 
 This dissertation investigates the protein signaling chain in the dopamine-
mediated negative feedback pathway of pancreatic β cells. In the presence of 
dopamine, a reduction in the influx of calcium occurs, mediating the inhibition of glucose 
stimulated insulin secretion. The signaling cascade that occurs after stimulation of the 
dopamine receptor, causing calcium channels to close, is currently unknown; however, 
it can be hypothesized from other dopamine receptor pathways which signal through the 
Gβγ complex to activate G-protein coupled inwardly-rectifying potassium channels 
(GIRK). GIRK activation causes the membrane to become hyperpolarized which causes 
voltage gated calcium channels to close. I hypothesize that activation of GIRK, through 
the Gβγ complex, occurs after stimulation of the dopamine receptor in β cells. To test 
this hypothesis, I measured protein interactions with fluorescence fluctuation 
spectroscopy (FFS).  FFS is a single molecule imaging technique capable of detecting 
diffusion rates and heteromerization between proteins. This first chapter introduces the 
anatomical and physiological background essential to understanding the biological 
question.  
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Figure 1 Anatomy of pancreas and its relation to duodenum and arteries. (from (1)) 
 
Physiology of Endocrine Pancreas 
Pancreas Physiology 
 The pancreas is an organ located behind the stomach, with a portion touching 
the first part of the small intestine, or duodenum as illustrated in figure 1. It performs two 
main functions, aiding digestion and regulating blood glucose (2–5). While one organ, 
the pancreas is made up of two portions, an exocrine and an endocrine portion. The 
exocrine pancreas, 95% of the pancreas, produces enzymes which aid in digestion, 
such as proteases to digest proteins, amylase to digest sugars, and lipase to digest fat 
(6).  These digestive enzymes are released into ducts which join to form the pancreatic 
duct and then onto the ampulla of Vater which releases the digestive enzymes into the 
duodenum (2, 3). The endocrine pancreas is composed of small micro-organs called 
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islets of Langerhans. The cells composing the islets are responsible for the production 
and secretion of hormones by the pancreas, including insulin and glucagon. The islets 
of Langerhans, while dispersed throughout the pancreas, are highly vascularized 
allowing for efficient release of hormones into the arteries (7). 
Islets of Langerhans 
 The Islets of Langerhans, hereafter referred to as islets, are micro-organs 
consisting of α, β, δ, and pancreatic polypeptide (also labeled γ cells), and ε cells (8). 
These cells produce and secrete glucagon, insulin, somatostatin, pancreatic polypeptide 
hormone, and ghrelin, respectively, into the bloodstream. While their specific cell 
functions are conserved, the makeup and distribution of each cell type of murine and 
human islets differ. Murine islets, commonly used for lab studies, are composed of 
roughly 80% β, 15% α cells and less than 5% of δ, γ, and ε cells (9, 10). They are 
formed by a central cluster of β cells surrounded by a layer of α and δ cells (11). In 
comparison, human islets are composed of roughly 60% β cells, 30% α cells, and 10% 
of δ, γ, and ε cells (12, 13). Previously, it was thought that these cell types were 
distributed homogenously throughout the islet; however, the current structure, accepted 
by the community, is more complex. A human islet is now considered to be structured 
as a cluster of small cell groupings, each of which is composed of a collection of β, α, δ, 
γ, and ε cells. Thus, together these small clusters of islet cell groupings form the whole 
human islet (10, 14)The differing cell compositions are seen after staining an islet for 
glucagon (α cells), insulin (β cells), and somatostatin (δ cells) as shown in figure 2. In 
addition to composition, human and mouse islets differ also in their size; a human islet 
is 50 ± 29 µm in diameter versus a wild-type mouse islet which measures 116 ± 80 µm 
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(10). While murine and human islets do have differences, they are similar in how they 
regulate blood glucose homeostasis (10)  
 
Figure 2 Insulin, glucagon, and somatostatin staining of islet from mouse (A) and human (B). In 
the mouse islet, a β-cell core is surrounded by α and δ cells. In contrast, the human islet is 
composed of small clusters of cells grouped together to form the larger islet. (from (11)) 
 
 The importance of islet structure is further seen when cell to cell communication 
is disrupted, via gap junctions. Gap junctions are small channels between cells which 
allow the passing of small molecules and ions. Through gap junctions, cells are able to 
equilibrate membrane potential between neighboring cells.  Studies performed on 
intracellular calcium levels show islets have an oscillatory response pattern in response 
to high glucose. To achieve a complex response pattern like this requires high levels of 
coordination (15). The loss of connexin 36, a gap junction protein found in islets, 
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disrupts the oscillatory response (16–19). The importance of islet architecture is 
additionally shown when islet cells are dispersed changing the amount of insulin and 
glucagon secreted compared to whole islets (9, 20–22).  
 In the pancreas, islets are highly vascularized with separate capillaries for 
endocrine and exocrine functions (7). Endocrine capillaries have thin walls and over 
70% more fenestrae in the capillary walls than exocrine capillaries, facilitating rapid 
molecule exchange (7).  Additionally, islets are highly innervated by parasympathetic, 
sympathetic, and sensory nerves (9, 10, 23). Parasympathetic stimulation increases the 
secretion of insulin, glucagon, somatostatin, and pancreatic polypeptide from islet cells 
(23–28). For example, parasympathetic nerve stimulation is responsible for the steep 
increase in insulin at the start of a meal. Thus, insulin can be increased before an 
increase in blood glucose is detectable. Parasympathetic nerves have likewise been 
shown to control glucagon secretion during hypoglycemia (29–31).  In contrast to 
parasympathetic stimulation, sympathetic neurons also control islet function by inhibiting 
insulin secretion and stimulating glucagon secretion. For example, norepinephrine is 
known to block insulin secretion and activate glucagon secretion (23, 30, 32). 
Furthermore, the neuropeptides released from neurons can directly activate G-protein 
coupled receptors (GPCRs) on the membrane. Acetylcholine, for instance, stimulates β 
cells to secrete insulin by directly activating the muscarinic acetylcholine receptors (23). 
Neural stimulation provides a secondary regulation of islet secretion to tightly control 
islet functions beyond blood glucose levels.  
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Blood Glucose Regulation 
 After a meal, blood glucose increases stimulating pancreatic β cells to secrete 
insulin. The presence of insulin causes cell tissues including adipose, muscle, and liver 
to uptake glucose in order to lower blood glucose levels (33, 34). In periods of 
starvation, or low blood glucose, pancreatic α cells secrete glucagon into the 
bloodstream. Glucagon acts mainly on the liver to stimulate glycogenolysis, the 
breakdown of glycogen to glucose. Increased production of glucose returns blood 
glucose to normal levels (33–35). While other factors additionally help regulate insulin 
and glucagon secretion, blood glucose concentration is the central driver illustrated in 
figure 3. Blood glucose severely below normal, hypoglycemia, and severely above 
normal, hyperglycemia, are severe health concerns (34). Through the secretion of 
insulin and glucagon, the body is able to achieve a narrow range of glucose in the 
bloodstream.  
 
Figure 3 Diagram showing blood glucose regulation. Adapted from Pearson Education, Inc. 2004 
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 Insulin and glucagon do not work independently; but concurrently to achieve 
normal blood glucose levels. To achieve glucose homeostasis faster after a meal, 
insulin secretion is increased and glucagon secretion is decreased. Conversely, during 
starvation glucagon secretion is increased and insulin secretion is decreased. Figure 4 
shows the levels of insulin and glucagon in the plasma and their effect on blood glucose 
levels after a meal. As blood glucose rises the amount of insulin secreted also 
increases, followed shortly thereafter by a decrease in glucagon secretion. Both the 
increase in insulin and decrease in glucagon allow the body to finely regulate the 
amount of glucose taken into the tissue. Thus, too much glucose taken into the tissue, 
resulting in hypoglycemia, does not occur. As blood glucose begins to decrease, insulin 
and glucagon return to their resting levels (36).  
 
Figure 4 Plasma glucose, insulin, and glucagon levels after a meal. (from (36))  
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Diabetes Mellitus 
 Diabetes Mellitus is characterized by chronic hyperglycemia, or high blood 
glucose. The name diabetes mellitus comes from syphon and sweet, noting the large 
amount of urination and high concentration of sugar in the urine of those with 
uncontrolled diabetes (2). Traditionally, diabetes has been divided into two broad 
classes, which are often thought of as different diseases as they are the result of 
different causes (2, 37). 
Type 1 
 Type 1 diabetes mellitus (T1DM) is a chronic autoimmune disorder where the 
body attacks β cells, destroying insulin production (37, 38). T1DM is most often 
diagnosed in children and young adults and is therefore often termed juvenile-onset 
diabetes although diagnosis can be at any age (37, 38). Since the body’s sensitivity to 
insulin is unchanged in T1DM, exogenous insulin is used to manage blood glucose 
levels (32).   
Type 2 
 In contrast to T1DM, type 2 diabetes mellitus (T2DM) is a chronic metabolic 
disorder characterized by insensitivity to insulin due to insulin resistance (39, 40). While 
not always the reason, increased caloric intake and decreased exercise, together, are 
the leading cause of insulin resistance. To compensate for the body becoming resistant 
to insulin, β cells begin to overproduce insulin to try to maintain normal blood glucose 
levels resulting in hyperinsulinemia. Continued stress on the β cells trying to produce 
large amounts of insulin leads to exhaustion and eventually β cell death (39, 41, 42). 
9 
 
The combination of decreased insulin sensitivity and insufficient production of insulin 
results in chronic hyperglycemia or T2DM.  
 Treating T2DM with insulin alone is sub-optimal as the body is insulin resistant. 
Therefore, one of the most effective therapies is weight loss and a reduced 
carbohydrate diet (40). Additionally, both oral and injectable pharmacological therapies 
have been developed to help manage T2DM. Meglitinides and sulfonylureas work by 
stimulating the release of insulin and are therefore often taken prior to meals  (43). 
Thiazolidinediones work by improving the body’s sensitivity to insulin in muscle and fat 
tissue and like biguanides (Metaformin) also decrease the amount of glucose produced 
by the liver (43, 44). Dipeptidyl-peptidase 4 (DPP-4) inhibitors work by inhibiting the 
breakdown of incretins which in turn stimulates the release of insulin and inhibits the 
release of glucose from the liver (45). Furthermore, alpha-glucosidase inhibitors reduce 
the breakdown of starches and sugars while sodium glucose transporter 2 (SGLT2) 
inhibitors block glucose from bring reabsorbed in the kidneys (46, 47). Last, amylin 
mimetics and incretin mimetics can be injected into the body to stimulate the release of 
insulin. While the list of treatments for T2DM is lengthy, each of these treatments is not 
without side effects and only serve to manage blood glucose levels, not treat the 
disease. Thus, further understanding of insulin regulation leading to better T2DM 
treatments is desirable. 
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G Protein Coupled Receptor Regulation of Insulin 
Introduction 
 G protein-coupled receptors (GPCR) are the largest family of membrane proteins 
with over 800 GPCR sequences being found in the human genome (48). Their function 
is to transmit signals outside the cell inwards so that the cell may respond appropriately 
(49).  Due to their ability to transmit signals into the cell, GPCRs are targeted for many 
therapeutics in a variety of ailments (50). It is estimated that fifty percent of current 
clinical drugs target a GPCR (51, 52). The ligands of GPCRs vary broadly, including 
ions, odorants, peptides and proteins, lipids, organic molecules (nucleotides, amines, 
fatty acids), and photons (48, 53). Just as varied as their ligands, the functions of 
GPCRs range from embryonic development, memory, vision, taste, and energy 
homeostasis to name a few (8, 54). Due to their diversity, two main classification 
systems exist. One methodology is the GRAFS system which groups receptors by a 
phylogenetic system: rhodopsin, adhesion, frizzled/taste, glutamate, and secretion (48). 
The second methodology is based on sequence homology and like-function forming 6 
classes, A-F: rhodopsin-like, secretion, metabotropic glutamate, fungal mating 
pheromone, cyclic AMP, and frizzled/smoothened (54). 
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Figure 5 Structure of GPCR (A) folded (B) (from (55)) 
 
G Protein-Coupled Receptor Structure 
 Characterized by their unique structure, GPCRs include seven hydrophobic 
transmembrane components structured in a counterclockwise arrangement to form a 
receptor. The transmembrane portions are between 20-28 amino acids and form α 
helices perpendicular to the membrane (56). The N terminus is located in the 
extracellular space, while the C terminus is intracellular (57). Three extracellular and 
three intracellular loops connect the seven transmembrane components as shown in 
figure 5. The extracellular loops and amino terminus are the most un-conserved 
sequence in GPCRs, contain glycosylation sites, and serve to control receptor actions 
(52, 56). A disulfide bond between the cysteines in the second and third extracellular 
loops promotes folding of the GPCR and regulates binding affinity (56). Conversely, the 
intracellular loops serve as binding sites for proteins including kinases and scaffolding 
proteins. The most conserved regions of GPCRs are the second and third intracellular 
loops which are known to be the binding sites of heterotrimeric G-proteins (58). Upon 
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the selected ligand binding, a conformational change of the receptor occurs, changing 
which amino acids can interact with proteins inside the cell (50, 57, 59). For efficient 
signal transduction, GPCRs exist in a dynamic equilibrium between inactive and active 
states (50, 59). Activation of the GPCR allows heterotrimeric G-proteins to disassociate 
where they in turn activate an intracellular signaling cascade.  
Heterotrimeric G-Proteins 
 Furthermore, GPCRs interact with heterotrimeric guanine nucleotide binding 
proteins, or G-proteins, to signal changes within the cell (48, 58). A heterotrimeric G-
protein is formed from three subunits: Gα, Gβ, and Gγ. In the inactivate state, the Gα 
subunit binds to both the GPCR and the Gβ subunit. The Gβ subunit is then bound to the 
Gγ subunit which is anchored to the membrane. The Gβγ functions to regulate Gα by 
increasing the affinity of Gα for GDP. The Gγ subunit additionally serves to enhance the 
interaction between the Gα subunit and the GPCR. When a ligand binds, a 
conformational change of the GPCR occurs and a guanosine diphosphate (GDP), 
bound to the Gα, is exchanged for a guanosine triphosphate (GTP).The bound GTP 
changes the conformation of the Gα causing it to disassociate from the GPCR and Gβ. 
The GTP-Gα initiates signaling of the cyclic AMP pathway while the Gβ and Gγ subunits 
stay attached as the Gβγ complex and signal to downstream targets, as shown in figure 
6 (60, 61). 
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Figure 6 GPCR activation diagram. When a ligand binds, the conformational state of the GPCR 
changes, causing the conversion of GDP -> GTP and releasing the Gα subunit from the GPCR and 
Gβγ complex. Gα then signals to downstream target proteins in the cyclic AMP pathway while the 
Gβγ complex activates a different set of target proteins. (from ((62)) 
 
 Compared to the large number of GPCRs, there are relatively few G-proteins; 21 
Gα subunits, 6 Gβ subunits, and 12 Gγ subunits exist in humans (63, 64). Heterotrimeric 
complexes are often categorized by the sequence of the Gα subunit: Gαs, Gαi, Gαq, and 
Gα12 (63). Post-translational modifications regulate membrane localization and protein-
protein interactions (65, 66). The Gβ subunit has a propeller structure formed by seven 
blades wrapped around a central axis as shown in figure 7. The N terminus of the Gβ 
has an alpha-helix which coils with the N terminus of the Gγ subunit. Additionally, the C 
terminus of the Gγ subunit binds to blades 5 and 6 of Gβ (67–69). This unique structure 
forms a bond between the Gβ and Gγ subunits so strong it is broken only by protein 
denaturing (60). Most of the Gβ and Gγ subunits have been shown to couple together 
and can interact with different Gα subunits (70). 
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Figure 7 Cartoon of crystalline structure of Gβ1γ1 complex (A). 7 blade propeller structure of Gβ in 
yellow with N terminus α helix attached to Gγ subunit (red). Gγ subunit also bound to blades 5 and 
6 of Gβ. The heterotrimer crystalline structure (B) where Gα (green) is bound to the Gβ1γ1 complex 
with the switch regions (blue) that allow conformational change and the release of the Gβ1γ1 
complex. (from (71)) 
 
GPCR in Islets (β-cell) 
 293 non-odorant GPCRs have been found to be expressed in human islets (53). 
Neurotransmitters, neuropeptides, and other ligands regulate islets by binding to cell 
surface receptors, oftentimes GPCRs, which then regulate islet functions (53, 72). The 
effect of many of these GPCRs are still unknown; GPCRs have been shown to have 
inhibitory and stimulatory effects on the secretion of insulin, glucagon, and somatostatin 
(53, 72). 
  
Dopamine 
Introduction 
 Dopamine is a neurotransmitter connected to emotional responses and rewards; 
however, it functions in a variety of signaling pathways (73). Dopamine plays a primary 
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role in the nigrostriatal (movement), mesolimbic (reward), mesocortical (cognitive 
control, emotional response), and tuberoinfundibular (lactation) systems of the brain 
(74–77). Due to its involvement in multiple brain pathways, many disorders have been 
linked to dopaminergic dysfunctions including schizophrenia, bipolar disorder, 
Parkinson’s disease, post-traumatic stress disorder, autism spectral disorder, alcohol 
dependency, nicotine dependency, impulsivity and violent behavior, attention deficit 
hyper disorder, and anxiety (78–90). As drugs to treat these disorders are developed, it 
is important to target specific receptor types and/or receptors in specific locations and 
pathways as to not disrupt other dopamine pathways.   
 The amino acid tyrosine is the precursor to catecholamines, figure 8, which 
include dopamine, norepinephrine, and epinephrine (91). Tyrosine hydroxylase adds an 
additional hydroxyl to tyrosine, creating L-Dopa, the predecessor to dopamine. Upon the 
removal of a carboxylic acid chain by L-Aromatic amino acid decarboxylase, dopamine 
is formed.  Dopamine β-hydroxylase removes a hydroxyl group from dopamine to then 
form norephinephrine which can then be methylated to form epinephrine by 
phenylethanolamine N-methyltransferase (91).  All three catecholamines are 
neurotransmitters which are released at axon terminals of nerve cells (2, 92).  
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Figure 8 The catecholamine biosynthetic pathway (from (91)) 
 
Dopamine Receptors 
 Dopamine receptors are G-protein coupled receptors separated into two groups, 
D1-like and D2-like. The D1-like receptors are part of the rhodopsin alpha family and the 
D2-like are beta-adrenergic receptors (48). The D1-like receptors, D1 and D5, work to 
regulate adenylyl cyclase activity by increasing cyclic AMP (73). In contrast, the D2-like 
family, composed of D2, D3, and D4, regulate adenylyl cyclase activity by decreasing 
17 
 
production of intracellular AMP (73). In contrast to the D1-like receptors, D2-like 
receptors contain introns which provide the ability for splice variants. Six introns are 
located in the gene encoding the D2 receptor, 5 in the D3 receptor gene, and 3 introns 
are in the D4 receptor gene (93). Two functional D2 receptors exist, a short (D2S) and a 
long (D2L) variant due to alternative splicing of the exon between the fourth and fifth 
introns. The D2 isoforms differ by the presence of an additional 29 amino acids in the 
third intracellular loop of the D2L (94). Multiple splice variants exist for the D3 dopamine 
receptor; however the physiological roles of the variants have yet to be studied (78, 93, 
95). Variants due to a 48 base-pair repeat in the third intracellular loop have been 
reported for the D4 receptor. These receptors are believed to be related to 
schizophrenia as changes in their affinity for the antipsychotic drug clozapine has been 
reported (96, 97). 
 Within the D2-like family, the D2 and D3 receptors have 78% of their genetic 
code conserved, making it difficult to find a receptor specific agonist/antagonist (98, 99). 
Differences in the third intracellular loop cause the D3 receptor to have a higher affinity 
for some agonists compared to the D2 receptor (78, 100). However, due to their 
similarities, at times both receptors have similar pharmacological properties (78). This is 
not always the case as it has been shown that activation of the D3 receptor decreases 
locomotive activity whereas activation of the D2 receptor increases locomotive activity 
(78). Some currently prescribed drugs for schizophrenia, olanzapine, clozapine, and 
risperidone have been shown to block both the D2 and D3 receptors, at times causing 
major side effects (98, 101, 102). While there are newer drugs which block only the D3 
receptor in animal models, they haven’t been tested in clinical trials due to their toxicity 
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(98).  The crystalline structure of the D3 dopamine receptor is shown with an agonist in 
figure 9. 
 In humans, the D2, D4, and D5 dopamine receptors are expressed in islets (53, 
103, 104). Furthermore, the GPR143 receptor, which is activated by the dopamine 
precursor L-Dopa, has also been shown to be expressed in human islets (53).  
 
Figure 9 Dopamine D3 receptor crystalline structure with antagonist eticlopride (purple)(from 
(105), Protein Data Bank ID 3pbl) 
 
Dopamine Mediated Negative Feedback Pathway 
Glucose Stimulated Insulin Secretion 
 In the presence of high glucose, pancreatic β cells secrete insulin into the 
bloodstream, signaling to tissues to uptake glucose and to the liver to increase glycogen 
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formation. At the cellular level of the β cell, shown in figure 10, glucose is taken up by 
glucose transporters (106) and then metabolized by the cell, resulting in an increase in 
the ATP to ADP ratio. One glucose molecule results in the net production of 36 ATP 
molecules. ATP sensitive potassium channels (KATP) close due to the change in the 
ATP/ADP ratio, depolarizing the membrane (8, 106). The depolarized membrane leads 
to the opening of L-type voltage gated calcium channels, triggering an increased influx 
of calcium. The increased intracellular calcium ([Ca2+]i) leads to the fusion of insulin 
granules to the plasma membrane for exocytosis (8, 106). The amount of glucose taken 
up by glucose transporters scales to the amount of insulin exocytosed by the β cell 
(106).  
 
Figure 10 Glucose stimulated insulin secretion (GSIS) pathway. 
 
Dopamine in Islets 
 In 1963, Falck and Hellman discovered catecholamines in the islets through 
formaldehyde-induced fluorescence (107). Subsequent studies investigated dopamine 
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and the actions of other cathecholamines upon islets and insulin secretion; however the 
results were inconclusive as certain studies showed insulin inhibition while others report 
increased insulin secretion in the presence of dopamine (108–112). In 1979, Zern et. al, 
showed that the effect of L-dopa to inhibit insulin secretion was due to the conversion of 
L-dopa to dopamine (113). Conflicting experiments reported L-dopa itself inhibited 
insulin secretion while dopamine was contained in secretory granules (114, 115). The 
origination of the dopamine, if not from the conversion of L-dopa, was not reported No 
dopaminergic neurons have been shown to innervate islets (4, 23, 24, 31, 116) and 
dopamine from the brain cannot cross the blood-brain barrier, therefore it was not clear 
from where this dopamine originated (117). Dopamine circulates in the blood stream, 
but the concentrations are too low to activate receptors in the islets (117–119). Two 
recent papers report the inhibition of GSIS in the presence of dopamine, one in mouse 
and one in human islets, and show that islets convert L-dopa to dopamine (120, 121). 
Furthermore, both papers report the co-secretion of dopamine and insulin (120, 121). In 
the human islet study, the authors show the presence of the D2 receptor in β cells and 
relate the inhibition of GSIS to its stimulation (121). However, in the murine islets 
studied, it was shown that the D3 dopamine receptor is the modulator of GSIS inhibition 
and not the D2 receptor, even though the D2 subtype is also present in murine β cells 
(120). It was further shown that reduced intracellular calcium ([Ca2+]i) oscillations 
following dopamine stimulation leads to decreased insulin secretion. These combined 
results support the proposed dopamine mediated negative feedback pathway to 
regulate insulin secretion which is further studied in this work. 
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Proposed Dopamine Mediated Negative Feedback Pathway 
 The published data shows that decreased frequency and amplitude of [Ca2+]i 
oscillations  inhibits insulin secretion.  Thus, we are interested in understanding the 
molecular signals that connect D3 dopamine receptor activation to the changes in 
[Ca2+]i. Unpublished work from our lab by Dr. Jacobson and Dr. Ustione, has shown that 
hyperpolarization after dopamine stimulation results from activation of a potassium 
channel other than the KATP channel. We hypothesize dopamine stimulation causes 
activation of G-protein inwardly rectifying potassium channels (GIRK) by signaling 
through the Gβγ complex of the G-proteins. In this model, movement of potassium out of 
the cell would result in plasma membrane hyperpolarization, causing voltage gated 
calcium channels to close. [Ca2+]i would thus be reduced in the cell and insulin secretion 
inhibited. A cartoon representation of GSIS and the proposed dopamine hypothesis is 
shown in figure 11. Because the islet can synthesize dopamine from L-dopa, dopamine 
can act as a method of regulating insulin secretion when both are secreted together 
(120, 121). In this work, I investigated this hypothesis by experiments focused on the 
heteromerization of the dopamine receptors and Gβγ complex before and after 
dopamine stimulation. Additionally, I studied the relationship between the Gβγ complex 
and hypothesized downstream target, GIRK.  
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Figure 11 Proposed Dopamine Mediated Negative Feedback Pathway 
 
 This dissertation is organized as follows: Theory and current applications of 
fluorescence fluctuations spectroscopy are presented in the second chapter. In the third 
chapter, I present the methodologies used in this work. I present experimental results of 
interactions between the dopamine receptors and G-proteins in the fourth chapter and 
interactions between G-proteins and the proposed target channel, GIRKs in the fifth 
chapter. This dissertation is concluded with the relation of this work to current literature 
and future directions.  
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CHAPTER 2 
 
FLUORESCENCE FLUCTUATION SPECTROSCOPY 
 
Tools for Understanding Protein–protein Interactions 
 There are many techniques to measure protein-protein interactions, some of the 
most popular are protein affinity chromatography, co-immunoprecipitation, and yeast 
two-hybrid screening. Protein affinity chromatography uses a column containing 
immobilized proteins. Cell extract proteins are then passed through the column. 
Proteins that do not interact with the immobilized proteins immediately flow through 
while those proteins that do interact are retained. Multiple ligands can be tested with a 
single receptor in protein affinity chromatography; however, proteins are out of their 
native cell environment and by using cell extracts, cells must be destroyed to perform 
protein affinity chromatography (122, 123). Similar to chromatography, 
immunoprecipitation can determine protein interactions by incubating cell extracts and 
an antibody. The antigen is then precipitated and the proteins eluted so they can be 
analyzed. Immunoprecipitations are often used as they are easy to perform and allow 
the testing of a whole cell extract at once (122). Both protein affinity chromatography 
and immunoprecipitation do not discriminate between two proteins interacting directly 
versus indirectly and require the cell to be lysed (122). In yeast two-hybrid screening, a 
bait and fish method is used to determine if two proteins are interacting. The protein of 
interest (the bait) is attached to the DNA binding domain of a transcription factor for the 
host, typically yeast. The proposed receptor (the fish) is bound to the activation domain 
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of the transcription factor. If the two bind together, a HIS reporter gene will be 
transcribed. If the two do not bind together the HIS reporter gene will not be transcribed 
and a new receptor (fish) is tried. Yeast two-hybrids are easy to perform, but they result 
in a high rate of false positives. Lastly, the reaction must be able to happen in yeast, 
often a non-native environment for the proteins of interest (124, 125).  
 
Figure 12 Three conditions must be met for FRET to occur. A. The donor fluorophore’s emission 
spectrum must overlap with the acceptor fluorophores excitation spectrum. B. The fluorophores 
must be in close proximity of each other, 10 nm apart, for the energy transfer between the two 
fluorophores to occur. Last, the two fluorophores must be oriented for dipole-dipole coupling to 
occur.  (from (126)) 
 
 In vivo and in situ methods, while more difficult to implement, have been 
developed to overcome the difficulties of in vitro protein interaction approaches. Unlike 
the in vitro methods, screening protein interactions are not easily performed within the 
cell and therefore these methods are not used to test many protein interactions at once. 
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Förster resonance energy transfer (FRET) measures the transfer of energy from one 
donor fluorophore in its excited state to an acceptor fluorophore through dipole-dipole 
coupling. FRET is commonly used in situ to measure protein interactions and 
biochemical reactions. Due to its popularity, many FRET sensors have been developed 
for easier application of the technique (127–129). However, FRET is not without 
drawbacks as it is often limited by low signal to noise ratios. Furthermore, both 
fluorophores must be properly aligned and within close proximity (<10 nm apart) to each 
other, shown in figure 12, resulting in high frequency of false negatives, even between 
two proteins which are known to interact (130). Like FRET, FFS detects weak and 
transient protein interactions in situ; however, FFS does not depend on the fluorophore 
proximity or orientation of the two fluorophores. Furthermore, the signal to noise ratio 
depends on the quantum efficiency of the fluorophores and the sensitivity of the 
detector. Current laser-scanning microscopes allow FFS measurements without 
specialized equipment which was previously required. Although artifacts from bleaching 
and intersystem crossing to the triplet state must be avoided, robust analysis 
procedures have been developed and are easy to implement on FFS data sets which 
are discussed below (131–135). 
 
Historical Background 
 In 1972, Magde, Elson, and Webb published the first papers on fluorescence 
fluctuation spectroscopy (FFS) (136–138), where they presented the technique that they 
called Fluorescence Correlation Spectroscopy (FCS) which was derived from dynamic 
light scattering. FCS was preferential to dynamic light scattering to measure particle 
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motion because fluorescent moieties could easily be attached to the molecules of 
interest and fluorescence is more chemically selective than light scattering (135). The 
optical setup from these early experiments is shown in figure 13. In 1976, Hirschfeld 
published the first application of fluorescence microscopy to detect single molecules; 
while not directly related to the FCS experiments, his work would lead to the 
development of modern FCS.  Without the development of detectors with higher 
quantum efficiency and stable lasers, FCS was not immediately applied  until the early 
1990s when Rigler’s group showed a confocal microscope could excite and measure 
fluorescence fluctuations (135). Confocal microscopy reduced the excitation volume; 
which in turn reduced the quantity of backscattered light which hindered early FCS 
experiments. The decreased noise from backscattered light additionally reduced 
integration times needed to quantify the fluctuations in a sample. Last, with the use of 
confocal microscopy based FCS, single photon counting methods could be for 
autocorrelation measurements. Due to the advancements made by Rigler’s group, FCS 
developments and applications greatly increased thereafter (139, 140).  
 
Figure 13 Schematic of optical setup from first FCS experiments. Excitation light from the laser 
passes through a colored filter (F), two spatial filters (SF) and through a lens (L) before exciting 
the sample. A laser intensity monitor (MON) measures the intensity at the sample. Emitted 
fluorescence is collected from a parabolic fluorescence-collecting mirror, passed through a filter 
and collected by a photomultiplier. (from ((137)) 
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 The next significant advancement in FCS was the development of two-color 
fluorescence cross-correlation spectroscopy (2cFCCS). Single color FCS can only 
detect binding between two molecules if the change in molecular size is increased or 
decreased by 10 times or more. Translational diffusion, D, is related to the size of a 
molecule as shown in equation 1 where k is Boltzmann’s constant, η is the viscosity of 
the solution, T is the temperature, and r is the hydrodynamic radius of the molecule.  
𝐷 =
𝑘𝑇
6𝜋𝜂𝑟
 
Equation 1 
The radius of the molecule, r, is related to its molecular weight, MW, by equations 2 and 
3 where ?̅? is the specific gravity and V is the volume. 
𝑉 = (𝑀𝑊)?̅? =
4
3
𝜋𝑟3 
Equation 2 
𝑟 =  (
3𝑀𝑊?̅?
4𝜋
)
1
3⁄
 
Equation 3 
A tenfold increase in the molecular weight results in only a 2.15-fold change in the 
diffusion coefficient. Thus, without large changes in molecular size when two molecules 
bind together, no detectable change in diffusion is measured by FCS. 2cFCCS tracks 
both molecules when they are bound and unbound and therefore can detect the 
presence of lack of interactions between both molecules independent of changes in 
molecular weight. 2cFCCS can be performed with one excitation beam; however, many 
of the original experiments performed with single photon excitation used two lasers to 
excite the two different fluorescent molecules (131, 141–144). When two beams are 
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used, both beams are overlapped to create the excitation volume. Each beam excites a 
different fluorophore, traditionally one green and one red (131, 141–144). Emission is 
collected and the two bandwidths are separated and detected independently. The 
intensity fluctuations in the two bandwidths are then cross-correlated and the probed 
interactions then analyzed. In this procedure, the cross-correlation curve is only a 
function of the fluctuations of both channels, not those of each channel independently. 
Because FCS measurements can be used to quantify the number of molecules in an 
excitation volume, 2cFCCS measurements quantify the number of bound molecules in 
relation to the unbound molecules of each channel (131, 141–144). While still 
implemented, one drawback of this technique is the need for two lasers with two 
imperfectly overlapping excitation volumes. Two-photon excitation provides the ability to 
excite two fluorophores of different emission wavelengths with one laser and therefore 
one excitation volume (145, 146).  
 Brightness analysis methods provided an additional technique to analyze 
fluorescence fluctuations. Fluorescence intensity distribution analysis (FIDA) and the 
photon counting histogram (PCH) were the first methods used to analyze the brightness 
of the fluctuating fluorophores (147, 148). Both methods, developed independently, 
analyze the moments of the fluorescence intensity distributions to determine the 
molecular brightness. With two component PCH, a heteromerization brightness 
component can be determined, relating to the extent to which two fluorophores are 
interacting with each other. A newer brightness analysis technique developed by Müller 
was a time-integrated fluorescent cumulant analysis (TIFCA) which uses the factorial 
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cumulants of the moments of fluorescence intensity distributions to resolve the 
compositions of heterogeneous mixtures (149–151).  
 To better probe samples, specifically biological samples, FFS has been 
combined with other microscopy imaging techniques. For example, image correlation 
spectroscopy (ICS) and Raster image correlation spectroscopy (RICS) measure particle 
movements by detecting fluorescence changes in successive images so that multiple 
spatial points can be tested in parallel (152, 153). ICS and RICS have been used to 
probe slow moving molecules in cells where single particle movement would be difficult 
and time consuming (152–156). Another recent application is scanning FCS (sFCS) 
where the excitation volume moves at a set rate on a predefined path during 
integrations. sFCS has been frequently applied to membrane measurements where 
localization of the membrane can be difficult. Because protein diffusion is slower at the 
membrane than cytoplasm the slowest diffusion rate coincides to the scanning of 
membrane bound proteins (157–160). These three techniques, while not an exhaustive 
list of the recent developments, highlight the improvements allowing better FFS 
measurements of biological samples.  
 
FFS Theory 
 In FFS, a small excitation volume of ~1 femtoliter excites fluorophores to a 
excited state. As molecules move into the excitation volume, fluorescence increases, 
and as they move out, fluorescence decreases. The fluctuations in the fluorescence is 
then collected, figure 14.  
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Figure 14 Schematic of FFS measurement. As molecules move in and out of the excitation 
volume, fluorescence will increase or decrease, respectively (A). Emitted fluorescent light is 
collected and a detector measure the intensity over time (B). C Intensity counts over time have 
small fluctuations, due to the movement of molecules in and out of the excitation volume, but a 
stable average count rate. 
 
The probability of a population of, n, being present in the excitation volume with the 
average number of molecules, N, is described by a Poisson distribution (161, 162). 
𝑃(𝑛, 𝑁) =  
𝑁𝑛
𝑛!
𝑒−𝑁 
Equation 4 
If molecules are diffusing at a high speed, the number of molecules within the excitation 
volume will also change rapidly. Molecules moving at a slow speed will enter and leave 
the excitation volume at a slower speed as shown in figure 15.  
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Figure 15 Schematic showing the differences between a slow diffusing molecule and a fast 
diffusing molecule. In the slow diffusing molecule, for a set lag time (τ) one count change has 
happened over the time frame. However, for the fast diffusing molecule, over the same lag time 3 
count changes have occurred. The autocorrelation function for the slow diffusion data would 
result in a wider curve indicating slower diffusion time whereas the faster fluctuations would 
result in a narrower autocorrelation curve indicating faster diffusion. (from (161)) 
 
FCS Theory 
 In FCS, two time points are denoted as t and t+τ to indicate the time difference, 
or lag time, between the two points. As τ approaches 0, fewer molecular diffusions 
occur and therefore the two time points should be strongly correlated. As τ increases, 
more molecules have entered and exited the excitation volume and therefore the two 
time points are expected to be less correlated. This is the central theory of 
autocorrelation, explained mathematically in Equation 5 (163). 
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〈𝑏(𝑡)𝑏(𝑡)〉 ≤ 〈𝑏(𝑡)𝑏(𝑡 + 𝜏)〉 
Equation 5 
  Two variables which are correlated will change together whereas two 
uncorrelated variables will change independently of each other. In FFS, one is 
interested in the changes in fluorescent signals from a sample containing fluorescent 
fluorophores. FFS fluctuations can be from chemical reactions, enzymatic reactions, 
translational diffusion, rotational diffusion, and photophysical transactions (135, 161, 
164, 165). The fluorescence fluctuations occurring from a sample over time relate to the 
reaction happening in the excitation volume. At short lag times, less changes in the 
excitation volume have happened so fluctuations are dependent on each other. At long 
lag times, more fluctuations have occurred and we expect fluorescent counts to be 
independent of each other. Equation 5 can be normalized to obtain a value relating the 
amount of correlation between the time points (163). 
𝑔 =  
〈𝑏(𝑡)𝑏(𝑡 + 𝜏)〉
〈𝑏(𝑡)𝑏(𝑡)〉
 
Equation 6 
If g is a measure of the correlation between the two time points, g will be greater than 1 
when variables are correlated, equal to 1 when uncorrelated, and 0 when anti-correlated 
(163). This is extended to fluorescence fluctuation counts as shown in Equation 7 (161, 
163). 
𝐺(𝜏) =  
〈𝐹(𝑡 + 𝜏)𝐹(𝑡)〉
〈𝐹(𝑡 + 𝜏)〉〈𝐹(𝑡)〉
=
〈𝐹(𝑡 + 𝜏)𝐹(𝑡)〉
〈𝐹(𝑡)〉2
 
Equation 7 
It is assumed that there are no changes over time to the statistical process occurring so 
that the average counts at both lag times are equal. 
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〈𝐹(𝑡 + 𝜏)〉 = 〈𝐹(𝑡)〉 
Equation 8 
Oftentimes, the autocorrelation function is written as the difference or change in 
fluctuations from the mean (161, 163). 
𝛿𝐹(𝑡) = 𝐹(𝑡) − 〈𝐹〉 
𝐺(𝜏) =
〈𝐹(𝑡 + 𝜏)𝐹(𝑡)〉
〈𝐹(𝑡)〉2
=  
〈(𝛿𝐹(𝑡 + 𝜏) + 〈𝐹〉)(𝛿𝐹(𝑡) + 〈𝐹〉)〉
〈(𝛿𝐹(𝑡) + 〈𝐹〉)〉2
=  
〈𝛿𝐹(𝑡 + 𝜏)𝛿𝐹(𝑡)〉 + 〈𝐹〉2
〈𝐹〉2
=  
〈𝛿𝐹(𝑡 + 𝜏)𝛿𝐹(𝑡)〉
〈𝐹(𝑡)〉2
+ 1 
Equation 9 
As shown above, there is only the additive difference of one between the two equations. 
The difference in fluorescent counts from the mean can be equated to the focal volume 
times the changes in concentration of the fluorescent probe within the volume (164). 
𝛿𝐹(𝑟, 𝑡) = 𝜙(ѓ)𝛿𝐶(𝑟, 𝑡) 
Equation 10 
Integrating over the focal volume defines the fluorescence signal itself (163, 164). 
𝐹(𝑡) = ∫ 𝜙(𝑟)𝛿𝐶(𝑟, 𝑡)𝑑3𝑟 
Equation 11 
The average fluorescence signal can then be derived to be (162) 
〈𝐹(𝑡)〉 = 〈𝐶(𝑡)〉 ∫ 𝜙(𝑟)𝑑3𝑟 
Equation 12 
Inserting Equation 10 and Equation 12 into Equation 9 results in the autocorrelation 
function written as (161, 162, 164) 
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𝐺(𝜏) =
∬ 𝜙(ѓ)𝜙(𝑟′)〈𝛿𝐶(𝑟, 𝑡)𝛿𝐶(𝑟′, 𝑡 + 𝜏)〉𝑑3𝑟𝑑3𝑟′
[〈𝐶(𝑡)〉𝜙(ѓ)𝑑3𝑟]2
 
Equation 13 
where 〈𝛿𝐶(𝑟, 𝑡)𝛿𝐶(𝑟′, 𝑡 + 𝜏)〉 is the correlation function of a concentration fluctuation at 
point ѓ at time t and a concentration fluctuation at point 𝑟′ and time t+τ (164). As 𝜏 → 0, 
Equation 13 reduces to the shape function (𝛾 = √2
2
 for 2-photon excitation) divided by 
the number of molecules in the excitation volume (161, 162). 
𝐺(0) = 𝛾
〈𝛿𝐶(𝑡)2〉
〈𝐶(𝑡)〉2
= 𝛾
1
𝑁
 
Equation 14 
For a data set, the autocorrelation function is computed in Fourier space as follows 
(162) 
𝐶𝑜𝑟𝑟{𝐼(𝑡), 𝐼(𝑡 + 𝜏)} ↔ 𝐼(𝑓)𝐼∗(𝑓) 
Equation 15 
 
 
Figure 16 Fluorescence fluctuations can be used to calculate the autocorrelation curve. The 
higher the concentration of fluorescent molecules, the lower the y-intercept (G(0)). Additionally, 
the width of the autocorrelation function relates to the diffusion rate of the fluorophore. The faster 
the diffusion, the narrower the autocorrelation curve will be. The slower the diffusion of the 
molecule, the wider the autocorrelation curve will be. (from (166)) 
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 From the autocorrelation curve, diffusion rate and fluorophore concentration can 
be calculated from fitting the curve.  Equation 14 relates the inverse of the y-intercept of 
the autocorrelation function (G(0)) to the number of fluorescent molecules. In the 
autocorrelation curve, a higher concentration of fluorophores results in a lower y-
intercept. The autocorrelation function also holds valuable information about the 
diffusion rate of the fluorescent molecule. A fast diffusing molecule that undergoes 
many changes for long lag times, as shown in figure 16, results in a narrower 
autocorrelation curve. Conversely, molecules diffusing slower in the excitation volume 
result in a wider autocorrelation curve. 
PCH Theory 
 Photon counting histogram (PCH) analysis and fluorescence intensity distribution 
analysis (FIDA) both examine the fluctuations of fluorescence as molecules diffuse in 
and out of the small excitation volume (147). They differ only in the model used to 
describe the excitation volume, but both perform essentially the same analysis and 
therefore arrive to the same conclusions. PCH has become the more popular of the two 
methods and is the methodology used in this dissertation. In Equation 4, I related the 
probability of a population of fluorophores, n, being in the excitation volume to a Poisson 
distribution. By definition, in a Poisson distribution the variance is equal to the mean.  
〈∆𝑛2〉 = 〈𝑛〉 
Equation 16 
This is the case for a stable excitation source; however, any fluctuations in intensity 
causes the variance to grow larger than the mean. Fluorescence intensity at a detector 
is therefore equal to the point spread function of the excitation volume, 𝑃𝑆𝐹̅̅ ̅̅ ̅(𝑟), the 
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intensity at the origin, 𝐼𝑜, and a coefficient relating to quantum yield and efficiency of the 
detector and microscope, 𝛽 (148). 
𝐼𝐷 = 𝐼𝑜𝛽𝑃𝑆𝐹̅̅ ̅̅ ̅(𝑟) 
Equation 17 
The Poisson distribution can thus be written with 𝑁 = 𝜂𝐼𝐼𝐷 where 𝜂𝐼 is proportional to 
detection efficiency (148, 162). 
𝑃(𝑛) =  ∫
𝜂𝐼𝐼𝐷
𝑛𝑒−𝜂𝐼𝐼𝐷
𝑛!
∞
0
𝑝(𝐼𝐷)𝑑𝐼𝐷 = ∫ 𝑃𝑜𝑖(𝑛,
∞
0
𝜂𝐼𝐼𝐷)𝑝(𝐼𝐷)𝑑𝐼𝐷 
Equation 18 
For the case of a single particle where 𝜀 = 𝛽𝜂𝐼𝐼𝑜 (molecular brightness), Equation 18 
can be written as Equation 19 (148). 
𝑝(1)(𝑘; 𝑉𝑜, 𝜀) =  ∫ 𝑃𝑜𝑖(𝑛, 𝜀𝑃𝑆𝐹̅̅ ̅̅ ̅̅ ̅(𝑟) 
∞
0
)𝑝(𝑟)𝑑𝑟 
Equation 19 
Because the particle must be confined within the volume 𝑉𝑜 to be detected, Equation 19 
can be rewritten as Equation 20 (148). 
𝑝(1)(𝑘; 𝑉𝑜, 𝜀) =  
1
𝑉𝑜
∫ 𝑃𝑜𝑖(𝑛, 𝜀𝑃𝑆𝐹̅̅ ̅̅ ̅̅ ̅(𝑟)) 
𝑉𝑜
𝑑𝑟 
Equation 20 
Extending this case for multiple independent particles as shown in Equation 21 (148). 
𝑝(𝑁)(𝑘; 𝑉𝑜, 𝜀) =  ∫ … ∫ 𝑃𝑜𝑖(𝑛, ∑ 𝜀𝑖𝑃𝑆𝐹̅̅ ̅̅ ̅(𝑟𝑖⃗⃗ )
𝑁
𝑖=1
𝑝(𝑟1⃗⃗⃗ ⃗) … 𝑝(𝑟𝑁⃗⃗⃗⃗⃗) 𝑑𝑟1 … 𝑑𝑟𝑁 
Equation 21 
While this equation looks difficult to evaluate, it is simplified by the fact that the 
probability distribution for a sum of statistically independent variables is the convolution 
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of the probability distribution of those variables (148, 167). Equation 21 can therefore be 
simplified to Equation 22. Thus, PCH is the convolution of the average number of single 
particles within the volume (148). 
 
𝑝(𝑁)(𝑘; 𝑉𝑜, 𝜀) =  
{𝑝(1)(𝑘; 𝑉𝑜, 𝜀) ⊗ … ⊗ 𝑝
(1)(𝑘; 𝑉𝑜, 𝜀)}
𝑁 − 𝑡𝑖𝑚𝑒𝑠
=  〈𝑝(𝑁)(𝑘; 𝑉𝑜, 𝜀)〉𝑁 
Equation 22 
 
FFS Measurements 
Instrumentation 
 Modern FFS setups are based on the confocal instrumentation introduced by 
Rigler (139, 140, 163, 165), shown in figure 17. The main requirements for FFS 
measurements are an excitation source, excitation mode, and a detection mode (137, 
163). The excitation source is a low power laser with low beam divergence and 
Gaussian spatial mode. It is important to have low laser power in FFS studies so that 
the fluorophore emission is in its linear range in proportion to excitation power. While 
single photon excitation (SPE) is still popular for FFS studies, many researchers are 
moving towards two photon excitation (TPE). TPE uses a pulsed infrared laser which is 
more costly than SPE lasers; however, TPE allows deeper penetration and causes less 
bleaching in the sample (143, 168, 169).  
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Figure 17 Optical setup based on the confocal instrumentation introduced by Rigler. Single 
photon excitation (left) and two photon excitation (right) S indicates the sample, OB objective 
lens; L lens; DM dichroic mirror; NF notch filter; T tube lens; PH pinhole; BS beamsplitter; APD 
avalanche photodiode; CORR correlator. (from (165)) 
 
 To excite a sample, laser light is focused into a high magnification microscope 
objective. High numerical apertures are necessary for FFS experiments to obtain a 
diffraction limited focal volume and high fluorescence emission collection (165). Oil 
immersion objectives with a high NA can be used; however, with deep aqueous 
solutions, optical aberrations occur (165). Therefore, water immersion objectives are 
generally preferred. The same objective lens is also used to collect fluorescence. For 
SPE, a pinhole is placed at the confocal plane to remove fluorescence due to out-of-
focus light. Photomultiplier tubes (PMT), avalanche photodiodes (APD), complementary 
metal-oxide-semiconductor (CMOS) and electron multiplying charge-coupled device 
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cameras (EMCCD) have all been used to detect fluorescent counts in FFS experiments. 
When selecting a detector, the detection rate must be higher than the expected diffusion 
rate of the molecule. Thus, it is necessary that detectors have high quantum efficiency 
to optimize signal-to-noise at high detection rates. Historically, APDs have been the 
preferred detector; however, new GaAsP PMT detectors are recently becoming the 
common FFS detector, figure 18 (165).  
 
Figure 18 Detector setup for Zeiss LSM 780. Emission beam paths is spectrally separated with a 
diffraction grating and detected by PMT detectors or an array of GaAsP detectors (from (170)) 
 
 In this dissertation, a Ti:Sapphire laser was chosen to excite samples at 1000nm 
which excites both the green and red fluorophores. Light was focused the sample with a 
40X, 1.2NA, water immersion objective. Emitted fluorescence was collected with the 
same objective and spectrally separated. 34 GaAsP detectors collected the light in 10 
nm bins (171).  
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 To optimize the FFS signal, the following properties of the selected fluorescent 
tag, dye or protein, are of greatest significance: high quantum yield, high photostability, 
and low singlet-to-triplet state quantum yield. The signal for FFS depends on the 
brightness of a few excited fluorophores, therefore it is important to choose fluorophores 
with high emission per molecule. Photobleaching can cause molecules to appear that 
they are diffusing faster than they are; thus fluorophores with high photostability are 
preferred in FFS experiments (172). Last, fluorophores with low singlet-to-triplet 
quantum yield is desirable as triplet state emission can distort the correlation function.  
Single Component Measurements 
 In single component FFS measurements, one fluorescent probe is used to 
monitor fluctuations in the system. Even with a single fluorescent marker, a significant 
quantity of information can be gained about the system, in addition to fluorophore 
concentration and diffusion rate (135, 161, 164). Boukari studied the formation of tubulin 
aggregation with FFS. When cryptophycin, a protein that promotes tubulin aggregation, 
was added to the sample, the diffusion rate decreased 250%, indicating homerization of 
tubulin particles (173).  
 FFS can also be used to study protein binding through changes in the diffusion 
rate of the labeled molecule. However, to adequately detect changes in solution due to 
the interaction of molecules, the molecular weight must increase ~10 times for the 
change in diffusion to be seen. Pack and colleagues studied the interactions between a 
partially denatured protein α-Lactalbumin with a chaperonin protein GroEL which 
promotes protein folding (174). The denatured α-Lactalbumin has a molecular weight of 
14,000 whereas the GroEL’s molecular weight is 840,000. Therefore, the binding of α-
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Lactalbumin to the GroEL will result in molecular weight increase larger than ten times. 
Pack showed the binding of GroEL altered the diffusion rate of α-Lactalbumin, which 
indicates the GroEL was promoting proper folding of α-Lactalbumin (174). Most single 
component FFS studies measure changes in diffusion or homerization; however, with 
the development of unique sensors other applications have been performed. For 
example, Webb’s lab developed a pH sensor with FFS. At low pH levels EGFP 
becomes quenched due to an ionized hydroxyl group and thus a portion of EGFP 
molecules become quenched faster than they diffuse in and out of the volume. These 
molecules therefore look to be diffusing faster than they really are. Webb’s lab showed 
the portion of molecules diffusing at a perceived faster rate is proportional to the pH 
level (146).  
 FCS is most commonly used to probe translational diffusion of molecules. 
Correlation in three dimensions with two-photon excitation is calculated by (161) 
〈𝛿𝐶(𝑟, 𝑡)𝛿𝐶(𝑟′, 𝑡 + 𝜏)〉 =  𝐶̅(8𝜋𝐷𝑡)
3
2⁄ exp [−|𝑟 − 𝑟′|2/8𝐷𝑡] 
Equation 23 
Inserting into Equation 13 results in Equation 24 which can easily be fitted to the 
autocorrelation points of the experimental data (164, 165, 175).  
𝐺(𝜏) = 𝐺(0) (1 +
8𝐷𝑡
𝑤𝑥2
)
−1
(1 +
8𝐷𝑡
𝑤𝑧2
)
−1 2⁄
 
Equation 24 
In the special case where two diffusion rates exist for a single probe (bound and 
unbound protein for example), the autocorrelation function is additive of each 
constituent (165, 175). 
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𝐺(𝜏) =  
1
𝑁2
[𝑁1𝐷1(𝜏) + 𝑁2𝐷2(𝜏)] 
Equation 25 
The last important fitting model is for lateral diffusion, for example, protein diffusion 
upon a membrane. In this case, only the 2D component is necessary from Equation 24 
(175–178).  
𝐺(𝜏) = 𝐺(0) (1 +
8𝐷𝑡
𝑤𝑥2
)
−1
 
Equation 26 
Through the combinations of Equations 24-26, many autocorrelation curves can be 
adequately fitted to determine diffusion rates and molecular concentration.  
 
Figure 19 Schematic showing emission counts from both the green and red channel are 
independent from each other as molecules are independently labeled with the fluorophores. 
Molecules diffusing together however, will change the counts simultaneously. The cross-
correlation is the co-diffusion of green and red labeled molecules diffusing together. (adapted 
from (161)) 
 
43 
 
Two-Color Cross-Correlation Measurements 
 In two-color FFS, two fluorescent probes label two separate fluorescent labels. 
Due to the weak relation between molecular weight and diffusion, many 
heteromerization processes cannot be detected by probing a system with a single 
fluorophore. However, with the invention of two-color FFS, heteromerizations that are 
not caused by a large change in molecular weight can be detected (179, 180). 
Traditionally, 2cFFS is performed with a green and red fluorophore, relating to the green 
and red channels, respectively (131, 181). Fluctuations of each channel are measured 
independently and therefore, two autocorrelation curves are formed. Because the green 
and red labeled proteins are independent of each other, different time-dependent 
fluctuations will occur in each channel independently of each other (figure 19). Changes 
that occur simultaneously relate to the co-dependence of both labeled molecules (131, 
181). Thus, the measured cross-correlation is dependent upon the relation between 
fluctuations in the green and red channel upon each other. The cross-correlation 
function can therefore be defined as Equation 27, where G represents the green 
channel and R represents the red channel (131, 146). 
𝐺𝐶𝐶(𝜏) =  
〈𝐹𝐺(𝑡 + 𝜏)𝐹𝑅(𝑡)〉
〈𝐹𝐺(𝑡)〉〈𝐹𝑅(𝑡)〉
 
Equation 27 
In figure 20, two autocorrelation curves and their cross-correlation curve are shown. As 
with the y-intercept of autocorrelation curves, G(0) of the cross-correlation curve also 
relates to the number of molecules present in the system. A change in the amount of 
interacting particles can therefore be determined by the ratio of cross-correlated 
particles to the independent species (131, 141, 182, 183).   
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Figure 20 Autocorrelation curves (green, red) and their cross-correlation curve showing the 
interaction of green and red molecules diffusing together. 
 
 Historically, many 2cFFS measurements have been performed with two different 
excitation lasers, one to excite the green channel and one to excite the red channel 
(131). The introduction of two lasers causes two point spread functions that do not 
perfectly overlap, leading to increased calibrations and analysis to determine cross-
correlation parameters (131, 183). The use of a single, two-photon excitation path 
removes these difficulties as a single laser is able to excite both channels at the same 
time.  
 
Photon Counting Histogram 
Single Component PCH 
 PCH analysis uses the same fluorescent fluctuation data which is gathered to 
derive an autocorrelation curve. A histogram is made by plotting the occurrence against 
the number of photon counts in each time bin, as show in figure 21. Oftentimes, as 
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shown in the insert, the PCH is plotted on a semi-logarithmic scale to see the 
differences in the super-Poisson distribution formed by PCH as compared to a Poisson 
distribution. The histogram is then fit to the model (Equation 22) to determine the 
molecular brightness and sample concentration.  
 
Figure 21 Photon Counting Histogram 
 
 An advantage of PCH analysis over FCS is the ability to resolve two species with 
similar diffusion coefficients from differences in their molecular brightness. For example, 
Kask and colleagues were able to separate Rhodamine 6G and tetramethylrhodamine 
(TMR) and their proportions in a mixture through brightness analysis (147). Since both 
are rhodamine derivatives, their diffusion rates are similar and therefore are inseparable 
as a mixture by FCS. TMR is much dimmer than Rhodamine 6G (37kcpsm vs 
107kcpsm) which allows the ability to distinguish and quantify both constituents by 
brightness analysis.  
 Current studies using PCH analysis have examined homerization of proteins in 
cells.  A current hypothesis for some GPCR proteins is their diffusion on the membrane 
together. Herrick-Davis used PCH analysis to examine the homerization of  the 
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Serotonin 5-Hydroxytryptamine 2C receptor and determined the protein diffuses in 
dimers on the membrane (184).  Another report show the use of PCH to determine how 
the ABCG2 subunits combine into tetramers to form a functional transporter (185). 
While single component PCH analysis continues to be used to analyze homerization, a 
derivation of the technique developed by Paul Wiseman’s group called spatial intensity 
distribution analysis (SpIDA) has simplified histogram analysis. SpIDA resolves protein 
oligomerization from single fluorescence microscopy images through histogram analysis 
(186–188). The technique is innovative as it can be applied to measure protein 
interactions from confocal images without the additional need of FFS equipment. 
Additionally, it is open source code and given as a Matlab graphical user interface for 
easy application. With the advent of this technique, histogram analysis has become 
more accessible to labs without FFS equipment. 
Two Component PCH 
 Two-component PCH allows for the detection of heteromerization between two 
different fluorescently labeled molecules (132, 134, 189). As shown in figure 22, a 3 
dimensional histogram is created to show the photon counts from the red and green 
channel. The heteromerization of the two channels is determined by their interaction, 
shown by high counts in the diagonal of the 3 dimensional histogram. The 
heteromerization brightness component can be calculated (independently of sampling 
time) by Equation 28. 
⟨𝜀𝑔𝑟⟩ =
𝜎2
𝑔𝑟
𝛾√𝐼𝑔𝐼𝑟
 
Equation 28 
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 The most common application of dual-color histogram analysis is for the probing 
of protein oligomerizaton. For example, the Giese lab uses 2d-FIDA to examine 
aggregation of the protein a-synuclein with lipid vesicles in the pathogenesis of 
Parkinson’s disease. Both, the a-synuclein and lipid particles, form homo-oligomers 
before combining together, making the heteromerization difficult to study with other 
protein-protein interaction detection methods (190, 191).  
 
Figure 22 Two component histograms showing the counts from the red channel on the vertical 
access and counts from the green channel on the horizontal axis. In single component 
measurements, counts are distinctly shown to be from that channel only. For non-interacting 
species, the heat map shows counts from both channels, but independent of each other. For two 
interacting species (doubled labeled) the histogram is centered in the diagonal, between the two 
channels. (from (192)) 
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 In this dissertation FFS is used to study the signaling between a GPCR, G-
proteins, and a downstream target channel. Using two-photon excitation, one excitation 
volume can be used to excite two channels simultaneously. The autocorrelation curves 
from FFS measurements are used to calculate protein diffusion rates. Additionally, the 
cross-correlation curve formed provides information on the heteromerization between 
the two proteins being studied. Two proteins diffusing together on the membrane should 
have a higher cross-correlation component than two proteins diffusing apart. As a 
secondary analysis method, the heteromerization brightness component from dual-color 
PCH analysis is also calculated.  To our knowledge, this is the first time FCCS and PCH 
have been used together to quantify protein oligomerization.  
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CHAPTER 3 
 
METHODOLOGY 
 
Introduction 
 In this chapter, I detail my procedures for taking FFS measurements. Proper cell 
preparation and instrument alignment are necessary each time measurements are 
taken. With FFS, the fewer molecules you can excite, the easier changes in fluctuations 
can be determined (175, 193). For example, it is easier to notice a change of 1 from 10 
than 1 from 100. When looking for changes in fluctuations, it is easier to detect small 
changes in fluorescence with small average counts than small changes in fluorescence 
with large average counts. In solution studies, dilutions are easy to perform so that 
fewer molecules are within the excitation volume. For cells, one cannot easily dilute the 
amount of proteins expressed. Therefore, it is oftentimes the dimmest cells which FFS 
measurements can be performed on. In addition to expression levels, calibration of the 
microscope and proper alignment are essential to obtaining good measurements. If the 
beam does not properly fill the back aperture of the objective, the actual excitation 
volume will differ from the expected beam shape used to calculate diffusion rates. Each 
time FFS measurements are performed, alignment should be checked. With proper cell 
expression and instrument alignment, FFS measurements can be performed. 
 In this chapter, I first describe the chosen cell line, culture protocols, and 
transfection procedures. Next, I describe the instrument experiments were performed on 
and alignment methods followed by explanations of the modifications I made to plasmid 
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constructs which I used in this dissertation. Following, I detail the first experiments 
which I performed measuring protein diffusion in solution and in the cell. Last in this 
chapter, I present diffusion measurements of membrane proteins taken by FFS in 
comparison to those previously reported by fluorescence recovery after photobleaching 
(FRAP) (194). 
 
Cell Preparation 
MIN6 Cell Line 
 Primary cells are often a preferred method to study biological processes in vitro 
as the only significant modification made to the cell is removing them from the 
organism. In comparison to immortalized cell lines which are often additionally modified 
genetically or virally, the behavior of primary cells is expected to be closer to that of in 
vivo. However, primary cells are more difficult to maintain than an immortalized cell line. 
For the purpose of this dissertation, the MIN6 cell line was selected for all experiments 
due to its retained response to secrete insulin under high glucose conditions and not 
during low glucose (195, 196). From previous research, we know that under glucose 
stimulated insulin secretion (GSIS) the treatment dopamine inhibits insulin secretion 
(120). Since the inhibition of insulin secretion by dopamine is further studied in this 
dissertation, it is essential that the β cell line chosen retains its response to secrete 
insulin under high glucose conditions.  
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Cell Media and Culturing 
 Cells were maintained in a sodium bicarbonate Dulbecco’s modified Eagle’s 
medium (DMEM) with 25mM glucose, 1mM sodium pyruvate, and 4mM L-glutamine. 
Additionally, Penicillin (100 units/ml), streptomycin (100µg/ml), 50µM of β-
mercaptoethanol, and a final dilution of 10% heat-activated fetal bovine serum were 
added to the media.   
 Media was exchanged at a minimum of every three days for healthy growth and 
proper pH ranges. Cells were split at 60-80% confluency with 0.25% Trypsin. After 
media neutralization, cells were pipetted up and down vigorously to break up clustering. 
Cells were plated at a minimum of 30% confluency.  Cells were cultured at 37° Celsius 
with 5% CO2. Low passages of cells are preferred as they retain better response to 
glucose stimulated insulin secretion; therefore, cells were only passaged up to 40 times 
(197). 
Cell Transfection Background 
 A chemical transfection method with effectene was initially used to transfect 
MIN6 cells. Chemical transfections are often preferred to other transfection methods 
because they produce high efficiency transfections, are easily reproducible, and require 
small amounts of nucleic acids (198, 199). Effectene forms non-liposomal, cationic lipids 
which deliver the nucleic acid plasmids to cells, shown in figure 1. The lipids formed by 
effectene are not disrupted by serum making it less toxic to cells than many other 
chemical transfections (199, 200). A typical transfection requires 1µL of DNA to 10µL of 
effectene and transfects one 10mm diameter imaging dish. However, by increasing the 
ratio of effectene to DNA, larger (and/or multiple) plasmids can be transfected in one 
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reaction. As I increased effectene to introduce the large dopamine receptor plasmids, I 
began to notice my cells exhibited cell rounding and were not as well attached to the 
imaging dish after transfection. Cell imaging dishes were coated with α-poly-l-lysine to 
increase cell adherence (201); however, this disrupted the effectene transfections and 
resulted in cells with high adhesion to the imaging dish, but with little to no transfected 
cells (201).  
 To combat the difficulties with chemical transfections, I chose the physical 
method of electroporation to transfect MIN6 cells. Electroporation uses an electric field 
to momentarily disrupt the membrane, as pictorially shown in figure 23. DNA in the 
surrounding solution can then enter the cell during these disruptions. I used a square 
wave electroporator which gave multiple, short electrical pulses to the cells. In contrast 
to chemical transfections, electroporation transfections can be difficult to implement as 
there are many variables which must be determined for an efficient transfection. These 
include pulse width, number of pulses, rest interval time, DNA concentration, cell 
density, and DNA to cell ratio. Additionally, electroporation requires a larger amount of 
DNA in comparison to the number of cells transfected than chemical transfections. 
However, transfecting multiple plasmids into the cells does not require additional 
alterations to a previously determined electroporation protocol.  Furthermore, 
electroporation transfections result in cells expressing the plasmids at a range of 
expression levels which is beneficial for FFS studies which require cells with low levels 
of expression  (198, 202). Furthermore I found the cells which survived the 
electroporation were adherent to the glass bottom of imaging dishes without the 
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requirement of secondary treatments. For these reasons, electroporation was chosen 
as the method of transient transfections in this dissertation. 
 
 
Figure 23 In an effectene reaction, an enhancer molecule is first mixed with DNA to condense the 
DNA. Condensed DNA is then mixed with the effectene reagent to form effectene-DNA complexes 
that the cell can endocytose. Conversely, in an electroporation reaction the electric field created 
from the applied voltage causes membrane pores to form. DNA can enter the cell through the 
pores formed during pulses. After the pulses, the cell membrane is healed and DNA that entered 
the cell during the pulses is inside the membrane. Cartoons adapted from Qiagen and BTX 
websites. 
 
Cell Electroporation Transfection 
 One day prior to imaging, cells were detached from culturing flasks with trypsin. 
Once cells were detached, cell media was used to inhibit further trypsin activity. The cell 
suspension was placed in a 15mL conical centrifuge tube and transported on ice to a 
centrifuge. Cells were pelleted at 300 RPM (the lowest centrifuge speed) at 4°C for two 
to three minutes. Pelleted cells were removed from centrifuge and placed on ice. 
Media/Trypsin mixture was carefully removed and cells were re-suspended in PBS + 
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1mM CaCl2 at 108 cells/ml. Forty microliters of the CaCl2 cell suspension was 
transferred to a 2mm-gap cuvette.  Ten micrograms of each plasmid, diluted in water to 
concentrations between 1,000-10,000 ng/ml, were placed in the cuvette. The 
cell/plasmid suspension was mixed by gently pipetting up and down prior to a 10 minute 
incubation period on ice. Cells were electroporated with a square wave electroporation 
system (BTX, Holliston, MA ) for 10 pulses lasting 50 µs at 300 V (1500 V/cm) with 
500ms intervals between each pulse. After electroporation, cells were diluted with warm 
media and plated on glass bottom dishes at a concentration of 1.5∙105 cells/cm2. Cells 
were incubated overnight and media was refreshed in the morning. Cells expressed 
plasmids properly for FFS measurements 24-48 hours after transfection.   
Cell Imaging Buffer 
 Cell media was replaced with a Krebs-Ringer Bicarbonate Buffer (KRBH) with 
.1% bovine serum albumin (BSA) and 12 mM glucose for imaging. Cells were washed 
twice with KRBH buffer before imaging to remove phenol red. For cells treated with 
dopamine, dopamine hydrochloride was diluted to 100 µM with warm KRBH buffer. Due 
to the rapid degradation of dopamine in solution, new dopamine solution was every 4 
hours. 
 
Instrumentation and Calibration 
General Overview 
 Cells were imaged on a LSM 780 confocal microscope (Zeiss). A tunable, mode-
locked Ti:Sapphire laser was used to excite fluorescence. Excitation light was guided 
into the microscope and passed through a 760 nm long-pass dichroic beam splitter 
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before entering a 40X 1.2NA water immersion objective used to focus the beam at the 
excitation point. Fluorescence excited at the focal point of the objective was collected 
with the same objective. Collected fluorescence is again passed through the 760 beam 
splitter to separate excitation and emitted light. The emitted light is spectrally separated 
and 31 detectors collecting in wavelength bins of 10 nm collect the light. Detectors are 
GaAsP Quasar detectors which have almost double the quantum efficiency of PMT 
detectors in the visible range (Zeiss, Jena, Germany). The multiple detectors allows two 
channel detection, green and red, without the use of filters. Additionally, accepted 
wavelengths for each channel can be determined within 10nm ranges. Figure 24 shows 
the emission spectra for EGFP and mApple. Between 550 nm and 600 nm the spectral 
emissions for EGFP and mApple overlap and cannot be separated. To avoid EGFP 
emission bleeding into the mApple channel, mApple emission collected between 600-
700 nm and EGFP emission was collected between 500-540 nm, shown in figure 24.   
  
 
Figure 24 Normalized emission intensity of EGFP and mApple with the emission collection 
regions highlighted. To avoid cross-talk between the green and red channels fluorescence 
emission was only collected at wavelengths where EGFP and mApple emission did not overlap. 
EGFP emission was collected between 500 – 540 nm and mApple emission between 600 – 700 nm.  
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Alignment 
 Proper alignment of the microscope was verified from measurements of the point 
spread function (PSF) using images of submicron fluorescent beads of 100 nm 
diameter. Z-stacks of X-Y plane images show the point spread function in 3 dimensions. 
Non-ellipsoidal PSF images indicated the instrument was misaligned. X-Y planar 
images from the submicron beads were used to determine the beam width through 
ImageJ Java Script Point Spread Function Estimation Tool (MOSAIC Lab) (203).  
Data Acquisition 
 FFS measurements require low average fluorescence count rates so that small 
changes in fluctuations can be determined. Preferred count rates are between 5-30 
thousand counts per second. This expression level, while low, is ten times greater than 
that autofluorescence. Figure 25 shows the fluorescent counts of two cells used for FFS 
measurements with a count rate of 6 kcps and 6.2 kcps. Also shown is scattering (.2 
kcps) and the autofluorescent counts from a cell not expressing the FP (.5 kcps).   
 
Figure 25 DIC and raster fluorescence image overlay of a cell properly expressing EGFP for FFS 
measurements (A) with contrast enhanced (B). At points 1 and 2, the count rate is within the range 
of 5-30 thousand counts per second. Also shown is the count rate for a cell not expressing EGFP 
(.5 kcps) and the count rate for the imaging buffer (.2 kcps). 
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 Measurement times for FFS experiments vary from 10 seconds to 120 seconds 
depending on the diffusion rate of the sample. Molecules in solution are typically 
diffusing at a fast rate where slower measurement times are adequate to fully describe 
the fluctuations (193). Slow moving membrane bound molecules require longer 
measurement times to fully define the fluctuations occurring. Long cell measurement 
times can be difficult to obtain due to cell movement and mechanical/optical drift in the 
system. To compromise for the long measurement times needed to fully describe 
fluctuations of molecules at the membrane and cell movement and instrument drift, 
measurements were taken for 45 seconds. This timeframe provided enough time for 
well resolved correlation curves while being fast enough to obtain measurements 
without average fluorescence count changes.  
 Previous literature has shown at temperatures below 37 °C, protein diffusion 
rates decrease (194, 204). Microscope incubators, which are often used to keep cells 
warm while imaging, are not able to be used for FFS studies of cells because they 
cause small vibrations which moves the excitation volume causing inaccurate 
measurements of specific cellular locations. To keep the cells warm without vibrations, I 
used an objective heater which was kept at 37 °C. Additionally, each cell dish was 
imaged for no longer than one and a half hours. If cells exhibited rounding or 
detachment, the dish was immediately discarded. 
 Diffusion rates of membrane proteins are under 1 µm2/s (193, 194, 205–208). 
During the long measurement times used in my cell experiments, FPs that do not move 
in and out of the excitation volume are bleached. Bleaching reduces the average 
fluorescent counts at a slower rate than fluctuations occurring due to diffusion. The slow 
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change in counts produces an autocorrelation curve that emphasizes the slow change 
bleaching over the fast fluctuations of diffusing molecules. An example of bleaching and 
the autocorrelation curve produced is shown in Figure 26.  To remove the artifact 
created by bleaching, an initial bleaching period is performed at the membrane before 
FFS measurements begin (175, 193). Once the slowly diffusing FPs are bleached, the 
average count rate is stable and fluctuations, occurring due to protein diffusion, can be 
measured.   
 
Figure 26 Average count rates during bleaching measurement (A) and the resulting FFS curve (B) 
which emphasizes the slow change in fluctuations due to bleaching instead of fluctuations due to 
protein diffusion.  
 
Data Analysis 
 Raw fluctuation data was saved after measurement for each channel 
independently. Included in the hexadecimal code is the file identifier, measurement 
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identifier, position, kinetic index, repetition number, detector frequency, and the first 
pulse distance between detector clocks prior to measurement counts (209). From the 
raw data files, fluctuations were binned (50 µs) and the autocorrelation curve computed 
in Matlab as described in Equation 29.  
𝐺(𝜏) =  
〈𝛿𝐼(𝑡)𝛿𝐼(𝑡 + 𝜏)〉
〈𝐼(𝑡)〉2
=
〈𝐼(𝑡)𝐼(𝑡 + 𝜏)〉
〈𝐼(𝑡)〉2
− 1 
Equation 29 
The autocorrelation curve is then fit to determine the diffusion coefficient. Fluorescence 
fluctuation measurements in solution and the cytoplasm were fitted applying a standard 
3D diffusion model.  
𝐺(𝜏) = 𝐺(0)
1
(1 + (𝜏 𝜏𝐷⁄ )) (1 + (
𝜔𝑧
𝜔𝑥𝑦⁄ )
−2
(𝜏 𝜏𝐷⁄ ))
1
2⁄
+ 𝐺(∞) 
Equation 30 
where ω denotes the beam dimensions. From the diffusion coefficient, τD, the diffusion 
rate can be determined.  
𝜏𝐷 =
𝜔2
8𝐷
 
Equation 31 
For membrane measurements, a two component 2D model was used to fit the data as 
detailed by Equation 32.  The slow diffusion component describes the membrane 
molecules diffusing on a 2 dimensional plane formed by the membrane. The fast 
diffusion component is due to the excitation of fluorescent molecules in the cytoplasm 
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underneath the membrane. This component, while presented, was removed for further 
analysis since it does not describe membrane proteins. 
𝐺(𝜏) =  
𝐴𝑓
1 + 𝜏 𝜏𝐷1⁄
+
𝐴(1 − 𝑓)
1 + (𝜏 𝜏𝐷2⁄ )
 
Equation 32 
To fit the measured autocorrelation curve, the least square curve fitting algorithm in 
Matlab was used. To determine protein interaction, the fluorescence cross-correlation 
component was determined, equation 33. 
𝐺𝐶𝐶 =  
𝐺𝑅𝐺
𝐺𝐺 + 𝐺𝑅
 
Equation 33 
 In addition to the cross-correlation, two component PCH was used to measure 
the heteromerization brightness component. Histograms of the fluctuations were formed 
by plotting the occurrence against the number of photon counts in each time bin. For a 
single particle excited by two-photon excitation, the PSF can be approximated by the 
square of a Gaussian-Lorentzian beam profile as define in equation 34 (148, 210) 
where 𝐼 is the light intensity, 𝐼𝑜 is the light intensity at the origin, and 𝜔 and 𝑧 are the 
beam waist in the horizontal and axial directions, respectively. 
𝑃𝑆𝐹̅̅ ̅̅ 2̅𝐺𝐿(𝑟, 𝑧) =  
𝐼2(𝑟, 𝑧)
𝐼𝑜2
=
4𝑤𝑜
2
𝜋2𝜔4(𝑧)
exp [−
4𝑟2
𝜔2(𝑧)
]  
Equation 34 
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In Chapter 2, I showed the PCH for a single particle can be written as equation 35. 
𝑝(1)(𝑘; 𝑉𝑜, 𝜀) =  
1
𝑉𝑜
∫ 𝑃𝑜𝑖(𝑛, 𝜀𝑃𝑆𝐹̅̅ ̅̅ ̅̅ ̅(𝑟)) 
𝑉𝑜
𝑑𝑟 
Equation 35 
Inserting equation 34 into 35, the PCH for a single particle in two-photon excitation can 
be determined (148) where 𝛾 is the incomplete gamma function. 
𝑝2𝐺𝐿
(1) (𝑘; 𝑉𝑜, 𝜀) =  
1
𝑉𝑜
𝜋24𝑤𝑜
2
2𝜆𝑘!
∫ (1 + 𝑥2)𝛾 (𝑘,
4𝜀
𝜋2(1 + 𝑥2)2
)
∞
0
𝑑𝑥 
Equation 36 
The experimental PCH is then fit to the convolution of the average number of single 
particles within the volume to determine the molecular brightness. The heteromerization 
brightness, two-color brightness, is determined by equation 37 (132). 
〈𝜀𝑔𝑟〉 =
𝜎𝑔𝑟
2
𝛾√〈𝐼𝑔〉〈𝐼𝑟〉
 
Equation 37 
 
Constructs 
 Many of the constructs used in this work were combinations of plasmids. Below, I 
will detail the changes I have made to the major plasmids used to transfect cells in this 
study. There were multiple constructs which did not produce a functional linkage of the 
protein of interest and fluorescent protein; these constructs are not discussed.  
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EGFP and mApple Bacterial Expression Plasmids 
 For measurements in solution, both EGFP and mApple pQe-9 bacterial 
expression plasmids were used to obtain purified fluorescent protein. The Qe9 vector 
has an N-terminus His6-tag used for protein purification and a selected resistance for 
Ampicillin through the β-lactamase (bla) gene.  Plasmids were transformed into BL21 
(DE3) competent Escherichia coli (E.coli) and plated on luria broth (LB) + ampicillin agar 
plates for overnight incubation at 37 °C. A single colony was picked and grown 
overnight at 37 °C while shaking in 5mL of LB with 5 mg/ml carbenicillin, an ampicillin 
analog with higher stability. A glycerol stock was made and frozen at -80 °C to remove 
the need for transformation and plating for each growth. One milliliter of overnight 
culture is grown in 50mL LB for 2-4 hours at 37 °C while shaking until an OD600 is 
reached. The colonies were then induced with Isopropyl β-D-1-thiogalactopyranoside 
(IPTG) and grown for 12-15 hours at 37°C while shaking. Many protocols instruct this 
last overnight growth to be at room temperature; however, I found no change in the 
amount of EGFP obtained and a reduction in the amount of mApple obtained when this 
last growth period was at room temperature compared to 37°C. After incubation cells 
were pelleted and frozen overnight before a His-tagged purification with Ni-NTA beads 
was performed to obtain purified proteins. 
EGFP and mApple Mammalian Expression Plasmids 
 EGFP and mApple mammalian expression plasmids were from Clontech N1 and 
C1 vectors which are resistant to kanamycin. Plasmids were transformed into DH5α E. 
coli for plasmid production. Colonies were selected and grown in 5mL volumes as done 
for the bacterial expression vectors described above. One milliliter of overnight culture 
63 
 
was placed into 50mL of LB with kanamycin and grown overnight at 37°C while shaking. 
The culture was then pelleted and a midi-prep kit protocol (Qiagen, Hilden, Germany) 
was used to obtain plasmid DNA. DNA was concentrated using ethanol precipitation 
and then re-suspended in distilled water to concentrations between 1,000-10,000 
ng/mL, the required DNA concentration for electroporation. The protocol explained 
above for plasmid production was reproduced for all mammalian expression cultures for 
transfections.  
EGFP DRD3 
 The dopamine receptor D3 (DRD3) labeled with EGFP on its N terminus was 
purchased from Addgene (Product Number 24098). The receptor is of human species 
and properly traffics to the membrane through the use of a nicotinic receptor α7 subunit 
signaling peptide (211, 212). The plasmid is of pCEP4 and is encoded for ampicillin 
resistance.  
EGFP DRD2 
 The D2 dopamine receptor (DRD2) labeled with EGFP on its N terminus was 
purchased from Addgene (Product Number 24099). Like the D3 receptor, the D2 is of 
human species and is properly trafficked to the membrane with the use of a nicotinic 
receptor α7 subunit signaling peptide (211, 212). The plasmid is in a pcDNA3.1+/Hygro 
backbone and is encoded for ampicillin resistance. 
mApple Gγ2 Subunit 
 The guanine nucleotide binding protein gamma-2 (Gγ2 or GNG2) was purchased 
as cDNA of mammalian origin from GE Life Sciences (product number MMM1013-
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7513168) and placed into a mApple C1 vector from Clontech between the restriction 
sites NheI (592) and BsrGI (1323). This GNG2 sequence has been used in many 
previous studies and has been shown to pair with the Gβ1 subunit to form a Gβγ complex 
(213–215). The plasmid encodes for kanamycin resistance.  
mApple Linked to EGFP construct 
 
Figure 27 mApple-EGFP plasmid from mApple C1 inserted into an EGFP N1 vector. The resulting 
construct has 18 amino acids separating the two fluorescent proteins.  
 
 As a positive control for FFS studies of interacting proteins, I constructed a 
mApple-18aa-EGFP construct where mApple and EGFP formed linked together by 18 
amino acids. PCR was used to amplify a mApple C1 insert between HindIII (623) and a 
KpnI restriction site added in the antisense primer (1361 added placement). EGFP N1 
and the mApple insert were digested at the indicated restriction sites and then ligated 
with T4 DNA Ligase.  A final plasmid map is shown in figure 27. 
65 
 
mCerulean Gβ1 Subunit 
 The guanine nucleotide binding protein beta-1 (Gβ1) subunit labeled with 
mCerulean at the N terminus was purchased from Addgene (product number 27810). 
This subunit is of human origination and has been well characterized to form functioning 
Gβγ complexes with Gγ2 (213–215).   
EGFP G-protein Inwardly Rectifying Potassium Channel 3 
 The G-protein Inwardly Rectifying Potassium Channel subunit 3 (KCNJ9, Kir3.3, 
GIRK3) was purchased from OriGene (product number 004983) labeled with turbo 
green fluorescent protein (tGFP) on its C terminus. The vector is a pCMV6-AC-GFP 
with the GIRK3 subunit inserted between SgfI and MluI and encodes for ampicillin 
resistance.  
mApple G-protein Inwardly Rectifying Potassium Channel 3 
 
Figure 28 GIRK3-mApple plasmid map formed by performing an in-fusion HD cloning kit to insert 
the GIRK3 subunit into the mApple N1 vector linearized at the AgeI restriction site. 
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 To measure interactions between the dopamine receptors and GIRK subunit, I 
used an in-fusion HD cloning kit to insert the GIRK subunit 3 sequence into a Clontech 
mApple N1 vector. For the reaction, the GIRK subunit was amplified by PCR and the 
mApple N1 vector linearized at the AgeI restriction site in the multiple cloning site. The 
final product formed was sequenced and its phenotype confirmed with a lambda scan, 
shown in Figure 28 with the full plasmid map.  
 
Protein Characterization 
 As an initial experiment, FFS measurements of EGFP and mApple in solution 
were performed and their diffusion rates compared to those previously reported by FFS 
experiments. mApple measurements also characterized the diffusion rate and 
brightness of mApple which has not previously been used in two-photon FFS studies. 
The diffusion rates for EGFP and mApple in solution were determined to be 71.2 ± 7.7 
µm2/s and 85.8 ± 15.8 µm2/s, respectively. Results are shown in figure 29 along with the 
results from previous FFS studies of green and red fluorescent proteins in solution 
(216–218). The measured diffusion rates are in agreement with the expected values of 
proteins diffusing in solution.  
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Figure 29 Comparison of diffusion rates determined for EGFP and mApple FPs versus those 
previously published (216–218). 2PE and SPE symbolize two-photon and single-photon excitation.  
 
 EGFP and mApple N1 plasmids were also expressed in MIN6 cells as a control 
experiment to confirm the diffusion rate of FPs within the cytoplasm could be correctly 
measured. Diffusion rates for EGFP and mApple were determined to be 22.4 ± 3.9 
µm2/s and 21.2 ± 4.8 µm2/s, respectively. The results can be compared to previous 
reported diffusion rates from FFS in figure 30. Both the EGFP and mApple FPs diffuse 
within the expected diffusion rate of FPs in the cytoplasm.  
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Figure 30 Diffusion rates of EGFP and mApple expressed within a cell versus previously 
published results of green and red FP diffusion rates in the cell. 
 
 As a control experiment to confirm the measurement of membrane proteins, two 
membrane proteins labeled with EGFP were measured in MIN6 cells and compared to 
previously reported diffusion rates of FRAP studies (194). The first of those proteins, 
transforming protein 21, or HRas, is an inner lipid protein used in signaling of the 
mitogen-activated protein kinases/extracellular signal-regulated kinases (MAPK/ERK) 
pathways (219, 220). HRas is similar to the Gγ subunit in that both are small, inner lipid 
proteins. The second control protein is VSVG3, a non-raft, transmembrane protein. FFS 
studies resulted in a diffusion rate of 0.90 ± 0.30 µm2/s for HRas and 0.34 ± 0.13 µm2/s  
for VSVG3, comparable to those found by FRAP (1.1 ± 0.40 µm2/s and 0.2 ± 0.10 
µm2/s, respectively) as shown in figure 31 (194). Thus, the diffusion rates of membrane 
bound and transmembrane proteins were properly measured by FFS.  
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Figure 31 Raster fluorescence image of HRas (A) and VSVG3 (B) tagged with EGFP; scale bar 5 
µm. Diffusion rates determined by FFS are 0.90 ± 0.30 µm2/s for HRas and 0.34 ± 0.13 µm2/s for 
VSVG3 compared to 1.2 ± 0.35 µm2/s and 0.2 ± 0.10 µm2/s for HRas and VSVG3 diffusion rates 
determined by FRAP (194) (C).  
 
Summary 
 Detailed in this chapter are the methodologies used for this dissertation and 
background studies required before performing the experiments later detailed. As 
described above, it is essential the instrument is set up and aligned properly in order to 
correctly measure fluctuations for the determination of diffusion rates and 
heteromerization of proteins. All constructs used in the experiments of this dissertation 
have also been described in full detail and plasmid maps provided for altered plasmids. 
Thus far, I have shown the ability to measure the diffusion rates of EGFP and mApple 
with two-photon excitation in solution and within the cell. Due to the slow diffusion rate 
of membrane proteins, I used FFS measurements to determine the diffusion rates of an 
inner-leaflet and transmembrane protein. Results were comparable to those determined 
by fluorescence recovery after photobleaching (FRAP).    
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CHAPTER 4 
 
DOPAMINE RECEPTOR SIGNALING THROUGH Gβγ COMPLEX 
 
Introduction 
 This chapter summarizes my studies of the signaling response by the dopamine 
receptor to the Gβγ complex, after stimulation. It has been shown that circulating L-dopa 
is taken up by the β-cells, converted into dopamine, and co-secreted with insulin (120, 
121).  In the presence of dopamine, [Ca2+]i is reduced, leading to decreased insulin 
secretion (120). This dopamine mediated negative feedback pathway regulates glucose 
stimulated insulin secretion (GSIS). Previous papers report the inhibition of GSIS by 
dopamine due to the D2 dopamine receptor subtype (120, 121, 221). However, in the 
presence of a D3 selective antagonist, insulin secretion is uninhibited while in the 
presence of a D2 selective antagonist, insulin secretion is predominantly inhibited (120). 
I hypothesize that the secreted dopamine is detected primarily by the dopamine 
receptor D3 subtype (DRD3), even though both the DRD2 and DRD3 subtypes are 
expressed in β-cells (120). Activation of the dopamine receptor leads to decreased 
[Ca2+]i, but the signaling pathway(s) from the receptor(s) to calcium activity remains 
unknown.  It was shown that adenylyl cyclase activity in β-cells is largely unchanged by 
dopamine stimulation (221), so I expect DRD3 to signal through release of the Gβγ 
complex.  To explore this pathway and determine which receptor is involved in the 
dopamine mediated negative feedback pathway, I want to examine the interaction 
dynamics of the D3 and D2 dopamine receptors and the Gβγ complex. 
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 Recent FFS studies have investigated membrane proteins to measure signaling, 
disassociation constants, and clustering (222–226). I have used two-color FFS to 
examine the specific activation of dopamine receptor sub-types in a pancreatic β-cell 
model.  Both cross-correlation and 2 component photon counting histogram analyses 
are applied to determine the dynamics of interactions between the DRD2 and DRD3 
receptors with their heterotrimeric G-proteins.  I show that both analysis methods yield 
the same results, which gives an internally consistent cross-check to the results.   
 
Materials and Methods 
Constructs and Cells  
 Enhanced green fluorescent protein (EGFP) and monomeric apple fluorescent 
protein (mApple) were expressed in MIN6 cells using Clontech N1 and C1 vectors 
(Clontech, Mountain View, CA).  For control experiments, mApple C1 was inserted into 
the EGFP N1 vector to form a linked mApple –EGFP construct with 18 amino acids 
separating the two proteins, as described in chapter 3.  EGFP-DRD3(211), EGFP-
DRD2 (211), and Gβ1-mCerulean(227) were obtained from Addgene (Cambridge, MA).  
The guanine nucleotide-binding protein subunit gamma-2 (Gγ2) cDNA was obtained 
from GE Lifesciences (Pittsburgh, PA) and inserted into the multiple cloning site of a 
mApple C1 vector (Clontech, Mountainview, CA) as further described in chapter 3. 
 Transient transfections were performed on MIN6 β-cells (196) by electroporation 
using an Electro Square Porator ECM 830 (BTX, Holliston, MA) as detailed in Chapter 
3.  For FFS data acquisition, the cell media was replace with Krebs-Ringer Bicarbonate 
buffer containing 1% BSA and 12 mM glucose.  Cells were warmed with an objective 
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heater maintained at 37 ºC.  For some measurements, 100 µM of dopamine 
hydrochloride (Sigma-Aldrich, St. Louis, Missouri) was dissolved in the imaging buffer. 
Instrumentation 
 Images and fluctuation measurements were performed on a LSM 780 using a 
40X NA 1.2 C-Apochromat water immersion objective lens (Carl Zeiss, Jena, Germany).  
Fluorescence was excited with a Chameleon Ultra Ti:Sapphire laser (Cohernet, Santa 
Clara, CA) running at 1000nm to provide a single excitation volume for both green and 
red channels.  Emission from GFP was collected between 500-540 nm and from 
mApple between 600-700 nm. The waist, ωo, of the excitation volume was determined 
to be 270±10 nm by measuring 100 nm fluorescent beads.  To determine the 
expression of cerulean, fluorescence was collected using an excitation wavelength of 
850 nm.  
 Signal levels below one thousand counts per second were determined to be the 
baseline of autofluorescence.  Typical FFS measurement of FP expression was 
between 10 to 50 thousand counts per second.  A Z-scan of 0.1 µm steps was used to 
center the excitation volume at the cell membrane.  FFS measurements were taken for 
45 seconds, and the first measurement at each position was removed to exclude initial 
bleaching of immobile labeled proteins (175). 
Theory and Data Analysis 
 Fluorescence fluctuation measurements in the cytosol were fit to a standard 3D 
diffusion model.  For membrane measurements, a two component 2D model was used 
to fit the data.  The results of the fast diffusion rate are shown, but these rates are not 
73 
 
consistent with the diffusion of membrane-bound constituents.  Thus, the slow 
component was used for further analysis as this represents the membrane bound 
proteins.  To determine protein interactions, the fluorescence cross-correlation 
component was determined (131, 228).  In a parallel analysis of the raw FFS data, two-
component photon counting histogram (PCH) analysis was used to evaluate the 
hetermoerized brightness component (132, 134).  An un-paired t-test was used to 
determine significant differences (GraphPad Prism, La Jolla, CA), and p-values less 
than .05 were considered significant. 
 Cell images were acquired using the ZEN software (Carl Zeiss, Jena, Germany).  
Fitting and cross-correlation data analysis was performed using in-house written 
MATLAB programs (Mathworks, Natick, MA).  Two-component PCH analysis was 
performed in ImageJ (NIH, Bethesda, MD) using a java script code modified for two-
photon excitation volumes from Jay Unruh’s source code (Stowers Institute, Kansas 
City, MO).  All graphs and data reported show mean ± standard error of the mean. 
 
Two-color FFS of Separate and Linked Fluorescent Proteins 
 To validate my measurements and analysis of the fluorescent protein labels used 
in these experiments, I first expressed each fluorescent protein label alone into MIN6 
cells and measured the fluorescence fluctuations in the cytosol of cells within the 
sufficiently low expression level required for fluorescence correlation measurements.  
For the enhanced green fluorescent protein (EGFP), a single species fit resulted in a 
measured diffusion rate of 22.4 ± 3.9 µm2/s, comparable with previous reported studies 
(216).  mApple has not previously been used for two-photon excitation FFS studies, but 
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its diffusion rate is expected to be equivalent to those of EGFP and other fluorescent 
proteins.  For mApple, the single species fits yields a diffusion rate of 21.2 ± 4.8 µm2/s, 
in agreement with other fluorescent proteins (216, 217).   
 
Figure 32 a. Autocorrelation curves from cells expressing separate EGFP (green) and mApple 
(red), and their cross-correlation (blue). b. Autocorrelation curves from cells expressing a linked 
EGFP (green)/mApple (red), with their cross-correlation (blue). Cross-correlation analysis (c) and 
two-component photon counting histogram analysis (d) quantifies the interaction of the unlinked 
and linked fluorescent proteins. 
 
 To establish the baseline cross-correlation between non-interacting proteins, 
separate EGFP and mApple plasmids were co-transfected into MIN6 cells.  Two-color 
FFS measurements were acquired from the cytosol and the cross-correlation curve was 
calculated (Figure 32a).  After fitting of the autocorrelation and cross-correlation curves, 
the interaction value, Gcc, was calculated.  This interaction was verified by a parallel 
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two-component photon counting histogram analysis of the same original FFS data to 
determine a heteromerization brightness component, <εcc> (Figure 32c,d).  
 To determine the maximal correlation between two fully interacting proteins, a 
plasmid was developed linking the two fluorescent proteins, EGFP and mApple, 
together with an 18 amino acid linker.  The plasmid was transfected into MIN6 cells and 
two-color FFS measurements were made from the cytosol (Figure 32b).  A cross-
correlation curve was computed and the interaction values, Gcc and <εcc>, were 
determined (Figure 32c,d), both giving a ~2.5 fold difference in correlation between the 
unlinked and linked constructs.  
 
Two-color FFS of Integral Membrane and Membrane Associated Proteins 
Single Component Diffusion of Dopamine D3 Receptor and Gγ Subunit 
To verify that the labeled proteins exhibit proper expression patterns and plasma 
membrane diffusion rates, I analyzed the FFS data to produce autocorrelation curves 
for labeled DRD3 and the Gγ subunit (GNG2).  As detailed below, the plasma 
membrane component diffusion rate was determined by fitting each curve.  The 
calculated diffusion rates for both of these constructs are comparable to other trans-
membrane and inner leaflet proteins analyzed by FRAP and/or FFS (194, 205–208).   
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Figure 33 a. Fluorescence image of MIN6 cells expressing EGFP labeled DRD3 – both plasma 
membrane and intracellular labeling are visible.  b. Experimental autocorrelation (dots) and two-
component fit (solid line). Scale bar is 5 µm. 
 
 Two-photon fluorescence images of DRD3-EGFP were acquired to determine the 
expression patterns of the labeled protein (Figure 33a).  The images show labeling both 
on the plasma membrane, and within the cytosol, putatively receptors located on 
intracellular membranes and recycling vesicles.  FFS measurements were taken from a 
diffraction limited spot centered on the plasma membrane.  A representative 
autocorrelation curve for DRD3-EGFP is presented in Figure 33b.  Multiple algorithms 
were explored to fit the autocorrelation curve, including single component diffusion, two 
component diffusion, and single component diffusion with an anomalous component.  
The two-component model resulted in the lowest residual sum of squares, suggesting a 
faster moving intracellular component and a slower moving fraction on the plasma 
membrane.  The slower diffusion rate of the plasma membrane, 0.120 ± 0.010 µm2/s 
component is in agreement with expected values (Figure 34).  Upon stimulation with 
100µM dopamine, I observed no protein expression changes in DRD3-EGFP, nor are 
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there any statistically significant differences in either its slow (0.108 ± 0.011 µm2/s) or 
fast diffusion rates between before and after dopamine exposure (p-value of 0.4208).   
 
Figure 34 Calculated diffusion rates for EGFP-DRD3 before and after treatment with 100 µM 
dopamine (p = 0.4208). 
  
 The Gγ subunit is one part of the heterotrimeric G-protein complex, which is 
known to signal as a dimer with a Gβ subunit (229).  There is great promiscuity among 
the different Gβ and Gγ subunits in the formation of dimers, and which complexes then 
form heterotrimeric G-proteins with different G-protein receptors.  I chose to use the Gγ2 
subunit due to its previous characterization and use in similar studies (230, 231).  The 
expressed Gγ subunit is expected to pair with intrinsic plasma membrane proteins in 
addition to the expressed DRD3.   
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Figure 35 a. Fluorescence image of MIN6 cells expressing the mApple labeled Gγ subunit – 
predominantly plasma membrane labeling is seen.  b. Experimental autocorrelation (dots) and 
two-component fit (solid line). Scale bar is 5 µm. 
 
 A representative fluorescence image of Gγ-mApple shows that the labeled 
subunits are largely membrane anchored, although a minor intracellular component is 
also observed (Figure 35a).  Figure 35b shows an autocorrelation curve obtained from a 
membrane FFS point measurement of the Gγ subunit.  A two-component fitting model 
was used to determine the diffusion rates.  The slower diffusion rate determined for Gγ-
mApple was 0.125 ± 0.016 µm2/s, which as for DRD3-EGFP, is in agreement with 
previous studies of plasma membrane proteins.  Since I expect the Gγ-mApple to be 
anchored to the plasma membrane, I did not expect to see significant changes in its 
diffusion upon dopamine stimulation, even if the G-proteins dissociate from the 
receptors.  This was confirmed in the data as the slow diffusion component was 
determined to be 0.091 ± 0.014 µm2/s after dopamine stimulation (Figure 36).  A t-test 
confirmed no statistical difference between the diffusion rates before and after treatment 
(p-value of 0.1195). 
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Figure 36 Calculated diffusion rates for mApple-Gγ subunit before and after treatment with 100 µM 
dopamine (p = 0.1195).   
 
Two-color Fluorescent Fluctuation Measurements of DRD3 and Gγ   
 To examine the potential signaling consequences of dynamic interactions 
between DRD3 and Gβγ complex, I co-expressed the fluorescently-tagged DRD3 and Gγ 
subunit.  Interactions between the dopamine receptor and the Gγ subunit were assayed 
by acquiring simultaneous two-color FFS measurements from a diffraction limited spot 
centered on the plasma membrane.  Two-photon fluorescence images of the two co-
expressed proteins (Figure 37a-c) show similar expression patterns to what is seen with 
each component expressed separately (Figure 33a, 35a).   
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Figure 37 Fluorescence images of MIN6 cells expressing EGFP-DRD3 (a), mApple-Gγ (b), and their 
overlay (c). 
 
 Representative cross-correlation curves reveal minimal interaction between the 
DRD3-EGFP and Gγ-mApple both before and after dopamine treatment (Figure 38a,b).  
The cross-correlation was determined to be 0.069 ± 0.011 without dopamine and 0.074 
± 0.007 with 100 µM dopamine treatment (Figure 38c).  A t-test revealed no statistical 
difference between the means of the cross-correlation component before and after 
treatment (p-value of 0.7287).  Using the parallel heteromerization brightness analysis, 
the interacting component was found to be 0.043 ± 0.006 before, and 0.032 ± 0.003 
after, 100 µM dopamine treatment (Figure 38d).  Similar as for the cross-correlation 
component, a t-test found no statistical difference between the two means of the 
brightness component before and after treatment (p-value of 0.0522).  This data was 
not consistent with the hypothesis that dissociation of the Gβγ subunit from the DRD3 
plays an important role in dopamine inhibition of insulin secretion. 
81 
 
 
Figure 38 Autocorrelation curves of EGFP-DRD3 (green), mApple-Gγ (red), and their cross-
correlation component (blue) before (a) and after (b) treatment with 100 µm dopamine.  FFS cross-
correlation (c) and heteromerization brightness analysis (d) before and after dopamine stimulation 
(p = 0.7287 and 0.0522, respectively).  Scale bar is 5 µm. 
 
Two-color Fluorescent Fluctuation Measurements of DRD3 and Gγ 
in the presence of Gβ  
 Since we know that dopamine activates DRD3 in β cells, I suspected that the 
lack of a measured change in the interactions between DRD3-EGFP and Gγ-mApple 
might result from a lack of sufficient numbers of Gβ subunits to form Gβγ complexes with 
the overexpressed Gγ subunits.  To investigate this possibility, I co-expressed a 
mCerulean labeled G-protein β subunit (Gβ1) with the labeled DRD3 and Gγ subunit.  
Previous studies have shown proper pairing of the Gγ2 and Gβ1 subunits (213–215).  The 
mCerulean fluorescent protein is not excited by two-photon excitation at 1000 nm 
(Figure 39a,b), which permits the two-color FFS experiments with DRD3-EGFP and Gγ-
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mApple to be performed without interference from the mCerulean fluorescence.  
Expression of Gβ1-cerulean was detected by fluorescence imaging with two-photon 
excitation at 850 nm (Figure 39c,d).  The resulting fluorescence spectrum (232) of a 
region of interest along the plasma membrane (Figure 8e) reveals the mCerulean 
emission as a shoulder around 470 nm that is not present with EGFP alone (Figure 
39e).  No changes in localization of the DRD3-EGFP or Gγ-mApple proteins are 
observed after addition of the third transfected protein (Figure 39a-d).   
 
 
Figure 39 Fluorescence images of MIN6 cells expressing EGFP-DRD3 (a), mApple-Gγ (b), 
mCerulean-Gβ (c), and the overlay of EGFP-DRD3 and mApple-Gγ (d).  e. Emission spectra (850 
nm excitation) of the plasma membrane region of a triply-transfected cell confirms expression of 
mCerulean-Gβ (fluorescence in the 450-490 nm range).  The emission spectrum of EGFP is shown 
for reference.  Scale bar is 5 µm. 
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        FFS measurements were taken from diffraction limited spots centered along the 
plasma membrane.  The autocorrelation and cross-correlation curves were calculated 
(Figure 40a,b), and interactions between DRD3 and the Gγ subunit were analyzed with 
two-color fluorescence cross-correlation analysis (Figure 40c).  Cross-correlation values 
were found to be 0.118 ± 0.016 before treatment and 0.065 ± 0.005 after treatment with 
100µM of dopamine (p-value of 0.0026).  Similarly, the heteromerization brightness 
component was calculated to be 0.043 ± 0.006 before and 0.026 ± 0.003 after the 
dopamine treatment (Figure 40d; p-value of 0.0054).  Both analyses are consistent with 
a significant reduction in the spatial association between the DRD3 and the Gγ subunit 
upon dopamine treatment.  
 
Figure 40 Autocorrelation curves of EGFP-DRD3 (green), mApple-Gγ (red), and their cross-
correlation component (blue) in the presence of mCerulean-Gβ before (a) and after (b) treatment 
with 100 µM dopamine.  FFS cross-correlation (c) and heteromerization brightness analysis (d) 
before and after dopamine stimulation (p = 0.0026 and 0.0054, respectively).  
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 The data shows a low correlation and no significant dopamine-associated 
changes between DRD3 and the Gβγ complex when I overexpress the fluorescently-
labeled DRD3 and Gγ subunit (Figure 38).  In this case, any Gβγ complexes formed with 
the labeled Gγ subunit would have to be paired with the native Gβ subunits.  My data 
suggest that this does not permit sufficient incorporation of the labeled Gγ subunit into 
active Gβγ complexes, as shown by relatively poor localization to the plasma membrane 
(Figure 37b) and low measured cross correlations (Figure 38c,d).  This is consistent 
with previous findings that overexpression of only the Gβ or Gγ subunit did not activate 
GIRK2 after stimulating the adenylyl cyclase receptor on oocytes (233).  Upon the 
additional expression of the Gβ1 subunit, which is known to pair with the Gγ2 subunit 
being used (213–215), I detected improved plasma membrane localization of the 
labeled Gγ subunit (Figure 39b), as well as higher heteromerization between labeled 
DRD3 and the Gβγ complex (Figure 40c,d).  The results suggest that it is important to 
overexpress all constituents of a functional complex for the extrinsic proteins to 
participate properly in the signal transduction pathway.   
 More than 40 different G-protein coupled receptors (GPCR) have been identified 
in the pancreatic β-cell, and it is expected that many of these receptors play important 
roles in the control of insulin secretion.  Thus, Gβγ complexes can associate and interact 
dynamically with a wide range of GPCRs, not only dopamine receptors.  Additionally, 
the overexpressed Gβ1 and Gγ2 can form complexes with other subunits native to the 
cell.  This is consistent with my analysis, which yields cross-correlation amplitudes that 
are small compared to the autocorrelation values.  This suggests that only a small 
number of the labeled proteins being within the interacting complexes, and is consistent 
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with the possibility that the labeled Gβγ subunits are interacting with multiple GPCRs.  
Despite these potential obstacles, I still measured the coupling between labeled DRD3 
and Gβγ complexes (Figure 40).  At baseline, there was a significant amount of 
heteromerization between DRD3 and the Gβγ complex, and this interaction was reduced 
after stimulation by dopamine.  This data is consistent with the hypothesis that DRD3 
signaling depends on release of the Gβγ subunit from the receptor following dopamine 
stimulation.  
Two-color Fluorescent Fluctuation Measurements of DRD2 and Gγ 
  Previous evidence suggests that dopamine signals preferentially through DRD3 
in β-cells, even though both DRD2 and DRD3 subtypes are present in the cells.  Thus, I 
examined whether dopamine-stimulated changes between DRD2 and the Gγ subunit 
are different than those measured for DRD3.  I performed FFS measurements between 
the DRD2 receptor and Gβγ complex using an EGFP labeled DRD2, with the same Gγ-
mApple and Gβ-mCerulean.  The localization of DRD2, Gγ subunit, and Gβ subunit 
expression was predominantly on the plasma membrane with some intracellular signal, 
similar to the results for DRD3 (Figure 41a-d).   
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Figure 41 Fluorescence images of MIN6 cells expressing EGFP-DRD2 (a), mApple-Gγ (b), 
mCerulean-Gβ (c), and the overlay of EGFP-DRD2 and mApple-Gγ (d).  Scale bar is 5 µm. 
 
 FFS measurements were performed at the membrane of cells properly 
expressing all three labeled proteins.  Autocorrelation and cross-correlation curves were 
computed from the measured fluctuations (Figure 42a,b).  Cross-correlation values 
were determined to be 0.075 ± 0.008 before treatment and 0.058 ± 0.005 after 
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treatment with 100µM dopamine (Figure 42c; p-value of 0.0702).  The heteromerization 
brightness components were determined to be 0.028 ± 0.003 before and 0.030 ± 0.002 
after the dopamine treatment (Figure 42d; p-value of 0.6289).  Unlike the results for 
DRD3 association, the FFS correlation between DRD2 and the Gγ subunit appears to 
be much less at baseline, and shows no statistically significant change upon dopamine 
stimulation. 
 
Figure 42 Autocorrelation curves of EGFP-DRD2 (green), mApple-Gγ (red), and their cross-
correlation component (blue) before (e) and after (f) treatment with 100 µm dopamine.  FFS cross-
correlation (g) and heteromerization brightness analysis (h) before and after dopamine stimulation 
(p= 0.0702 and 0.6289, respectively).   
 
 Previous work showed that dopamine inhibits the amplitude and frequency of 
[Ca2+]i oscillations in islet β-cells, leading to reduced insulin secretion (120).  That work 
also showed that dopamine signaling in β-cells is primarily mediated by DRD3, even 
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though both DRD2 and DRD3 are known to be present (120).  The results presented 
here suggest a possible solution to this dichotomy.  The data shows significant 
heteromerization between DRD3 and the Gβγ complex, and that this heteromerization is 
reduced in the presence of added dopamine (Figure 40).  However, I did not find 
significant changes in the heteromerization between DRD2 receptor and the Gβγ 
complex after dopamine treatment (Figure 42).  Taken together, these data strongly 
support the hypothesis that the dopamine feedback loop inhibits insulin secretion 
primarily by stimulation of DRD3.  The lack of dopamine-mediated changes in 
DRD2/Gβγ complex interactions could be due to initially low levels of G-protein coupling 
to the DRD2.  This would be consistent with the low cross-correlation and 
heteromerization brightness component values measured in my experiments.  Another 
possibility could be that the DRD2 receptors are mainly sequestered away from the 
plasma membrane, and therefore would not be accessible to extrinsically added 
dopamine.  This would be consistent with the findings of a previous paper that indicated 
the DRD2 expression was primarily within secretory granules (221).  Further work would 
be needed to distinguish between these two possibilities, but the results presented here 
provide a framework for these and other future studies. 
 
Summary 
 This chapter presents my study of interactions between the dopamine receptors 
and Gβγ subunits using two-color FFS.  Previous studies have used two photon 
excitation FFS cross-correlation to assay interactions between proteins labeled with 
EGFP and mCherry and monomeric red fluorescent protein (mRFP) (134, 217).  
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Because of its increased brightness over mCherry and mRFP, mApple is superior for 
FFS measurements (234).  I showed signals from EGFP and mApple can be separated 
and used to measure dynamic heteromerization changes by FFS.  
 I next tested the hypothesis that the D3 receptor is activated by dopamine 
stimulation by measuring interactions between the D3 dopamine receptor and Gγ 
subunit. No changes were observed after dopamine stimulation which was inconsistent 
with the proposed hypothesis. To determine if overexpression of both the Gβ and Gγ 
subunit was required to measure signaling, I additionally overexpressed the Gβ subunit 
labeled with mCerulean which is not excited at 1000 nm, the excitation wavelength I 
used for FFS measurements. Upon the co-expression of Gβ and Gγ subunits, I showed 
a reduction in heteromerization after dopamine treatment, confirming signaling through 
the D3 dopamine receptor. Next, I measured interactions between the D2 dopamine 
receptor and the Gβγ complex after dopamine stimulation and showed no 
heteromerization changes. Thus, my results confirm the preferential signaling through 
the D3 dopamine receptor over the D2 dopamine receptor in the feedback pathway 
(120, 221).   
 In these studies, I utilized both fluorescence cross-correlation spectroscopy 
(FCCS) (141, 235) and two-component photon counting histogram (PCH) analysis (132, 
236) methods to measure the interactions between dopamine receptors and their G-
proteins.  Previous biological studies of FFS have used only one analysis method or the 
other to examine the fluorescence fluctuations.  Here I showed both analysis methods 
yield similar results, both in terms of baseline interactions and changes in 
heteromerization of the labeled proteins.  Use of both analysis methods provides an 
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internally self-consistent check on the validity of the data and each separate analysis 
algorithm. 
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CHAPTER 5 
 
GIRK INTERACTIONS WITH Gβγ COMPLEX 
 
Introduction 
 The material in this chapter focuses on the experiments I performed investigating 
interactions between the G-protein inwardly rectifying potassium channel (GIRK) and 
the Gβγ complex. Once the D3 dopamine receptor is activated, [Ca2+]i is reduced (120). 
Unpublished work by Dr. Jacobson and Dr. Ustione shows that hyperpolarization of the 
membrane after dopamine stimulation results from potassium channel activation other 
than the KATP channel. We hypothesize dopamine stimulation causes activation of GIRK 
by signaling through the Gβγ complex of the G-proteins. In this model, movement of 
potassium out of the cell would result in plasma membrane hyperpolarization, causing 
voltage gated calcium channels to close. [Ca2+]i would thus be reduced in the cell and 
insulin secretion inhibited. The proposed dopamine mediated negative feedback 
pathway is shown in figure 43. I hypothesized after dopamine stimulation, activation of 
GIRK channels by the Gβγ complex would increase and therefore heteromerization 
would increase.  
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Figure 43 Proposed pathway for leading to decreased intracellular calcium and therefore 
decreased insulin secretion after stimulation with dopamine. Upon activation of the dopamine D3 
receptor, the Gβγ subunit activates G-protein inwardly rectifying potassium channels. The influx of 
potassium into the cell causes hyperpolarization of the membrane causing voltage gated calcium 
channels to close. The decreased calcium flux leads to a reduction in intracellular calcium, 
blocking insulin secretion. 
  
 GIRK channels, also known as Kir3, are members of the inwardly rectifying 
potassium channel family which includes Kir1-Kir7 (237). There are four GIRK subunits, 
GIRK1-4, also known as either Kir3.1-3.4 or KCNJ3, KCNJ6, KCNJ9, and KCNJ5, 
respectively. As identified by their name, GIRK channels are activated by G-proteins, 
specifically the Gβγ complex. Functioning GIRK channels are tetramers of four GIRK 
subunits. ). GIRK2 is the only subunit to form homotetramers (238, 239); however, all 
subunits form functional heterotetrameric channels in pairs (239–242). For example, two 
GIRK1 and two GIRK3 subunits form a functional GIRK channel. It has not yet been 
determined if functional channels are formed from three or four different type subunits 
(243). For the purposes in this work, GIRK3 was primarily studied due to its ability to 
form heterotetramers with all four other channels and the lack of splice variants found 
for it (240, 244, 245). By measuring GIRK3, a large number of GIRK channels can be 
examined with one overexpressed subunit. Most GIRK research to date has focused on 
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GIRK function in neural and cardiac pathways (246–248). In these pathways, multiple 
neurotransmitters including acetylcholine, adenosine, dopamine, serotonin,  and 
somatostatin have been shown to activate GIRK channels through stimulation of their 
G-protein coupled receptors (249–252). Expression of GIRK subunits has also been 
shown in the pancreas and pancreatic cell lines (253–258). Iwanir determined the co-
localization of all four GIRK subunits with insulin in pancreatic islets through 
immunolabeling and additionally, the presence of all four subunits in the insulinoma β 
cell line INS-1E (253).  
 
Materials and Methods 
Constructs and Cells 
 The turbo green fluorescent protein (tGFP) N terminus labeled GIRK3 subunit 
was purchased from Origene (MG205842, Rockville, MD). Multiple GIRK constructs 
were received from Tooraj Mirshahi at Geisinger Health System (Wilkes-Barre, PA) 
which are listed in Table 1 (259–261). The origination of the different subunits are 
varied; however, the proteins sequences are highly conserved. 
Table 1 GIRK subunits with their tagged labels and origination of each sequence used in the 
experiments described in this chapter. 
Subunit Label Terminus Origination 
GIRK1 Yellow Fluorescent Protein (YFP) C Human 
GIRK2 Green Fluorescent Protein (GFP) C Mouse 
GIRK4 Green Fluorescent Protein (GFP) C Rat 
GIRK4 Cerulean Fluorescent Protein (CFP) C Rat 
GIRK2 Human influenza hemagglutinin (HA) C Mouse 
GIRK3 *Origene EGFP N Mouse 
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 In order to perform two-color FFS measurements between the EGFP labeled 
dopamine receptor D3 and the tGFP labeled GIRK3 subunits, a new construct of GIRK3 
labeled with mApple was made with an in fusion HD kit (Clontech, Mountainview, CA). A 
further detailed description of the GIRK3-mApple is in Chapter 3.  
 Chemical transfections were performed with Effectene Transfection Reagent 
(Qiagen, Hilden, Germany). MIN6 cells were plated on glass bottom imaging dishes 
(Life Technologies, Carlsbad, CA) and incubated overnight to allow for recovery. Half a 
microgram of DNA was used for each plasmid and the effectene to DNA ratio was kept 
at 1:8. The amount of enhancer changed for the type of reaction and size of proteins 
involved. For EGFP-GIRK alone, 10µL, for EGFP-GIRK with the mApple labeled Gγ 
subunit, 20µL, and for mApple-GIRK and EGFP-DRD3, 30µL. Each 1mL effectene 
reaction was used to transfect one imaging dish. Typical expression incubation times 
were between 18-24 hours. After 48 hours, the expression levels were too high for FFS 
studies and cells were discarded. Electroporation transfections, used for two color 
measurements only, were performed using an Electro Square Porator ECM 830 (BTX, 
Holliston, MA) as detailed in Chapter 3.  
 For FFS data acquisition, the cell media was replace with Krebs-Ringer 
Bicarbonate buffer containing 1% BSA and 12 mM glucose.  Cells were warmed with an 
objective heater maintained at 37 ºC.  For some measurements, 100 µM of dopamine 
hydrochloride (Sigma-Aldrich, St. Louis, Missouri) was dissolved in the imaging buffer. 
Instrumentation 
 Raster fluorescence images and fluctuation measurements were taken on a LSM 
780 using a 40X NA 1.2 C-Aprochromat water immersion objective lens (Carl Zeiss, 
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Jena, Germany). Fluorescence was excited with a Chameleon Ultra Ti:Sapphire laser 
(Coherent, Santa Clara, CA) running at 1000nm to provide a single excitation volume 
for both green and red channels. Emission from GFP was collected between 500-540 
nm and from mApple between 600-700 nm.  
Data Analysis 
 Correlation curves were processed and fitted with MatLab programs and 
brightness analysis was performed with Java Script code in ImageJ, both described in 
Chapter 3.  
 
Expression of GIRK Subunits 
 To verify expression, a raster fluorescence image was taken of a MIN6 cell 
expressing tGFP-GIRK3 (Figure 44). Two components are detectible, an intracellular 
component and a plasma membrane component. One hypothesis for the large 
intracellular component is that only a single subunit, GIRK3, was expressed. This 
subunit alone cannot form functional GIRK channels. Overexpressed GIRK3 can only 
form functional channels with native GIRK subunits in the cell. The transient transfection 
introduced considerably more GIRK3 subunits than the cell needs to form the necessary 
GIRK channels for signal transduction. When performing Z-scans, membrane location 
could be determined, but with increased difficulty due to the large intracellular 
component of the GIRK subunits. 
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Figure 44 Two-photon excitation (1000 nm) raster fluorescence image of MIN6 cell expressing the 
turboGFP labeled GIRK3 subunit; A large intracellular component with a faint membrane outline 
can be seen to the upper right side of the cell; scale bar 5 µM 
  
 While all four GIRK subunit have been determined present in β cells, no 
consensus has been reached to the amounts of each subunit inherently in the cell, nor 
which GIRK channels are most often formed (253–258). Therefore, I decided to test the 
expression of each subunit transfected alone in MIN6 cells. The expression phenotypes 
for GIRK1, 2, and 4 are shown in figure 45. Both GIRK1 and GIRK2 have a high 
proportion of bright spots due to protein clustering, potentially due to endosomal 
compartments. However, only GIRK3 has a strong plasma membrane component that 
is easily distinguishable from the intracellular.  
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Figure 45  Representative raster fluorescence images of MIN6 cells expressing GIRK1-YFP (A), 
GIRK2-EGFP (B), tGFP-GIRK3 (C), and GIRK4-CFP.  Both GIRK1 and GIRK 2 both exhibit 
clustering throughout the cytosol and no plasma membrane bound component.(A, B); tGFP-
GIRK3 has small portions of membrane expression, but with a large intracellular component 
throughout the cell (C). GIRK4-CFP is distributed evenly throughout the cytosol with no plasma 
membrane component visible; scale bar 5 µM 
  
 Previous studies have shown that GIRK2 and GIRK3 form functional GIRK 
channels (241, 242). To increase the amount of GIRK2 in the cell for GIRK3 to pair with, 
I co-transfected GIRK2 labeled with an HA tag and GIRK3 labeled with a tGFP tag. 
Without a fluorescent label on the GIRK2 or the use of an anti-HA tag antibody, I was 
not able to determine which cells specifically expressed both subunits. A representative 
image of the co-transfection is shown in Error! Reference source not found.46; no 
cells exhibited a strong membrane component and cell rounding was present 
immediately when imaging started. In addition to the pairing of GIRK3 with GIRK2, I 
also tested the pairing of GIRK3 and GIRK4 to from functional channels at the 
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membrane. GIRK4 has been shown to be a critical subunit in the activation of GIRK 
channels in cardiac signaling (262, 263). Additionally, GIRK4 has been shown to be 
membrane localized when expressed alone and to support the transportation of other 
GIRK subunits to the membrane of oocytes (264). The co-expression of tGFP-GIRK3 
and GIRK4-CFP however resulted in a large intracellular component and no clearly 
defined membrane region. Experiments characterizing GIRK3 at the membrane were 
performed as detailed in the next section. Due to the insufficient signal of GIRK3 at the 
membrane, only initial measurements between GIRK3 and Gγ were performed.  
 
Figure 46 Representative raster fluorescence images of MIN6 cells expressing GIRK2-HA and 
tGFP-GIRK3 (A) and tGFP-GIRK3 and GIRK4-CFP (B); Co-expression of GIRK2-HA and tGFP-
GIRK3 cells exhibit a membrane component, a large intracellular component, protein clustering, 
and cell rounding indicating unhealthy cells. Cells co-transfected with tGFP-GIRK3 and GIRK4-
CFP result in expression throughout the cytosol with some clustering, but no plasma membrane 
bound component; scale bar 5 µM 
 
Two-color FFS of Integral Membrane and Membrane Associated Proteins 
Fluorescence Fluctuation Measurements of GIRK 
 Single color FFS measurements were taken at the membrane before and after 
treatment with 100µM of dopamine. As found for the dopamine receptor and Gβγ 
complex, a two component model resulted in the lowest residual sum of squares, 
signifying it as the best fit to the data. The slow diffusion rate, representing the 
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membrane bound component, was determined to be 0.38 ± 0.09 µm2/s before and 0.21 
± 0.03 µm2/s after dopamine treatment. The fast intracellular component is 13.09 ± 1.51 
µm2/s without dopamine and 11.46 ± 1.10 µm2/s with dopamine. A student t-test was 
performed and no statistical significance was determined between diffusion rates before 
and after dopamine treatment for either the slow or fast component as expected (p-
value of 0.0752 and 0.3932, respectively).  
 
Figure 47 Calculated diffusion rates from two component fitting of tGFP-GIRK3 before and after 
treatment with 100µM dopamine.  The slow diffusion rate represents the membrane bound 
component whereas the fast diffusion rate is due to the intracellular component. Unpaired t-test, 
p-value of 0.0752 and 0.3932 for the slow and fast diffusion rates, respectively. 
 
Two-color FFS measurements between GIRK3 and Gγ subunit 
 To test the relationship between a GIRK channel including the GIRK3 subunit 
and the Gβγ complex, tGFP-GIRK3 and mApple-Gγ were co-transfected into MIN6 cells. 
A representative raster fluorescence image is shown in figure 48. The mApple-Gγ is 
membrane bound while the tGFP-GIRK3 shows both a membrane and intracellular 
component. Two color FFS measurements were taken at the cell membrane and the 
autocorrelations and cross-correlation curves calculated. In my hypothesis, the Gβγ 
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complex activates GIRK channels so that an influx of K+ enters the cell. If correct, 
heteromerization between the GIRK and Gβγ complex would increase after dopamine 
treatment.  
 
Figure 48 Representative raster fluorescence images of MIN6 cells co-transfected with tGFP-
GIRK3 (A) and mApple-Gγ (B); merged (C). The expression of both labeled proteins is not altered 
by the co-transfection; scale bar 5 µM 
 
 Figure 49 shows two representative autocorrelation and cross-correlation curves 
between the labeled proteins for before (A) and after (B) dopamine. The horizontal 
slope and zero y-intercept show no correlation before or after treatment. Quantification 
of the cross-correlation (C) before and after dopamine treatment resulted in a Gcc of 
0.046 ± 0.010 and 0.052 ± 0.013, respectively. An unpaired t-test resulted in a p-value 
of 0.7110 indicating no statistical significance between the means of the cross-
correlation values. The heteromerization brightness component (D) results were in 
agreement with the cross-correlation results with a brightness component of 0.035 ± 
0.007 and 0.031 ± 0.009, for no treatment and with 100µM dopamine treatment 
respectively. An unpaired t-test again resulted in no measurable statistical difference 
between the two means with a p-value of 0.7518.  
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 These interaction analyses show no interaction between the GIRK3 and Gγ 
subunit. My data measuring interactions between the D3 dopamine receptor and Gβγ 
complexes, in Chapter 4, suggest the Gγ subunit is not sufficiently incorporated with the 
Gβ subunit unless both are overexpressed. To measure interaction between the Gβγ 
complex and GIRK channel, both the Gγ subunit and Gβ subunit may need to be 
transfected into the cell. 
 I selected GIRK3 for FFS measurements because it can form tetramers with all 
three other GIRK subunits to form functional channels allowing me to measure 
interactions between the Gβγ complex and multiple GIRK channels in one experiment 
(240, 244, 245). If the Gβγ complex signals to a GIRK channel not comprised of a GIRK3 
subunit, no interaction will be measured before or after dopamine treatment. 
Furthermore, based on previous dopamine receptor studies, I hypothesize the 
dopamine receptor signals to a GIRK channel through the Gβγ complex (250, 265, 266). 
If a different potassium channel (or calcium channel) is activated by the Gβγ complex no 
heteromerization between any GIRK subunit and the Gβγ complex would be measured. 
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Figure 49 Autocorrelation curves of tGFP-GIRK3 (green), mApple-Gγ (red), and their cross-
correlation component (blue) before (a) and after (b) treatment with 100 µM dopamine.  FFS cross-
correlation (c) and heteromerization brightness analysis (d) before and after dopamine stimulation 
(p = 0.7110 and 0.7518, respectively). 
 
Two-color FFS measurements between GIRK3 and Dopamine Receptor D3 
 Recent literature has shown the co-localization of GPCRs with their target 
proteins to allow for quick and efficient signal transduction (267, 268). Relationships 
between the receptor and target protein can be difficult to detect with many standard 
protein interaction techniques since the proteins are not strongly bound to each other. 
FFS provides a method to study in situ the relationship between the D3 dopamine 
receptor and GIRK channels. To test the proximity of the D3 receptor and GIRK3 
subunit, the EGFP labeled D3 dopamine receptor and mApple-GIRK3 were co-
transfected into MIN6 cells. The goal of this experiment was to take FFS measurements 
to determine if the two proteins diffused together on the membrane for rapid signal 
transduction from the D3 receptor to the GIRK channel. If the two proteins diffuse 
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together, an increase in the correlation and brightness component between the two 
proteins would be observed, compared to that seen for two non-interacting membrane 
proteins. Figure 50 shows raster fluorescence images of MIN6 cells transfected with 
both labeled proteins. Cells with both expressed proteins show unhealthy vesicles and 
exhibited cell rounding. Changes in the amount of DNA used to transfect the cells, 
electroporation versus chemical transfections, and shorter incubation times after 
transfection before imaging did not increase the number of healthy cells. Cells that 
expressed only one plasmid had varying expression levels and proper attachment to the 
bottom of the glass dishes. Experiments between the D3 receptor and GIRK channel 
were not taken due to the inability to obtain properly expressing and healthy cells. 
 
Figure 50 Representative raster fluorescence images of MIN6 cells co-transfected with EGFP-
DRD3 (A) and mApple-GIRK3 (B); merged (C). The expression of both labeled proteins is altered 
by co-transfection. Cells exhibited cell rounding and protein clustering not present when 
expressed independently; scale bar 5 µM 
 
Conclusion and Future Directions 
GIRK Channel Membrane Trafficking Difficulties 
 Without clear expression of the tGFP-GIRK3 at the membrane, it is likely that 
improper trafficking of the channel is occurring. An intracellular component is expected 
to be present since GIRK3 is only a subunit of GIRK channels and cannot form 
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functional channels alone; the large amount of intracellular component was 
unanticipated. The intrinsic GIRK subunits within the cell have not been knocked down 
for these measurements and therefore the introduced tGFP-GIRK3 subunit was 
expected to form functional channels with the intrinsic subunits. In the oocyte model, 
Mirshahi et al. showed GIRK1 did not traffic to the membrane on its own, but needed 
the additional expression of GIRK4 to form functional GIRK channels at the membrane 
(264). The co-transfection of GIRK3 and GIRK4 however resulted in intracellular 
components of the two proteins, no large plasma membrane component. Co-
transfections of GIRK2 and GIRK3, two subunits well studied to form functional tetramer 
channels, also showed no increased membrane localization of the channel subunits 
compared to GIRK3 alone (241, 242).  To properly measure the interactions of GIRK at 
the membrane, it is essential for proper membrane localization to occur. Future 
experiments should begin with determining which GIRK subunits are properly trafficked 
to the membrane alone and with other subunit pairings. Reverse transcriptase 
polymerase chain reaction (RT-PCR) can be used to detect RNA expression of the 
GIRK subunits in MIN6 cells (253).  Western and coimmunoprecipitation assays can 
then be used to detect pairings between subunits as previously performed for neural 
GIRK channels (241, 242). While GIRK1 and GIRK2 are known to pair with GIRK3 in 
the cell to form functional GIRK channels, there is reported variability with the current 
levels when the proteins are overexpressed into cells (241, 242, 269–271). The 
knowledge that splice variants exist for GIRK2 could be the result of this variability and 
therefore should be looked into when testing the co-expression with GIRK3 (240, 244, 
245).  Last, the GIRK1, GIRK2, and GIRK4 subunits obtained from Geisinger Health 
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System have all been co-expressed together in previously reported studies, but not with 
the GIRK3 subunit used here which was obtained separately. GIRK3 subunits from 
different originations should be tested to determine if the GIRK3 obtained does not 
properly couple with other GIRK subunits to form functioning channels. 
Lack of Activation Measured between GIRK Channel and D3 Receptor 
 In measurements between the dopamine receptor and Gβγ complex, it was 
necessary to express the Gβ and Gγ subunits to obtain a signal. Thus, it is probable that 
to measure interaction between the GIRK channels and Gβγ complex, both subunits in 
the Gβγ complex must be expressed.  
 When measuring the heteromerization between GIRK3 and Gγ subunit, it was 
expected to find an increased cross-correlation and heteromerization brightness 
component after dopamine treatment, indicating that the Gβγ complex activates the 
GIRK channel. The GIRK channel is G-protein gated and previous studies have shown 
activation of GIRK channels by the dopamine receptors (250, 265, 266). The lack of 
measured signaling could be the result of GIRKs not comprised of the GIRK3 subunit 
being activated by the dopamine receptor. GIRK3 was selected as it can form functional 
subunits with many different combinations of GIRKS, thus by selecting it a broad variety 
of channels could be sampled. GIRK1, GIRK2, and GIRK4 are all present in the β cell 
and comprise a minimum of four GIRK channels, not including splice variants, which are 
not sampled by labeling GIRK3 and thus should be studied further.  
Expression Difficulties between GIRK Channel and D3 Receptor 
 Co-transfections of the mApple labeled GIRK3 and EGFP labeled D3 dopamine 
receptor did not produce healthy cells for which to take FFS measurements. Varying the 
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amount of DNA used in electroporations and reducing the time after transfections for the 
protein to be produced in the cell did not alter the expression levels. As explained in 
chapter 3, electroporation transfections are preferred to chemical transfections for a 
variety of reasons helpful in FFS experiments. To further test for proper expression of 
both plasmids in healthy cells, chemical transfections were also performed with 
unsatisfactory results. I expect proper membrane localization of the labeled GIRK 
subunits after the proper GIRK subunit pairings are known, from western and 
coimmunoprecipitation assays. However, if proper membrane localization does not 
occur when co-expressing subunits that form functional GIRK channels on MIN6 cells, 
subunits originating from the same animal should be tested. Once proper membrane 
trafficking of the GIRK subunits is achieved, co-expression of the D3 receptor and GIRK 
subunit(s) should be performed. If cells are healthy and expression is plasma 
membrane localized, measurements between the D3 dopamine receptor and GIRK 
channel should be performed to determine if the GPCR and proposed target channel 
are in close proximity on the membrane. 
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CHAPTER 6  
 
CONCLUSION AND FUTURE DIRECTIONS 
 
Conclusion 
 The goal of this work was to use fluorescence fluctuation spectroscopy (FFS) to 
identify the signaling mechanism of the dopamine mediated negative feedback pathway 
in pancreatic β cells.  Previous studies have shown that islets can convert L-dopa to 
dopamine and then co-secrete dopamine with insulin (120, 121, 221). During glucose 
stimulated insulin secretion (GSIS), dopamine decreases intracellular calcium 
fluctuations in islets , which inhibits insulin secretion (120, 121, 221). The D2 dopamine 
receptor has been reported to be the receptor initiating the dopamine mediated negative 
feedback pathway (121, 221). However, both the D2 and D3 dopamine receptors have 
been found in β cells. Under a DRD3 selective inhibitor, the effect of dopamine on GSIS 
was ameliorated (120). but  islets treated with a DRD2 selective inhibitor still showed 
dopamine modulation of GSIS (120).  Thus, we hypothesized the dopamine mediated 
negative feedback pathway is initiated by the D3 receptor and not the D2 receptor.  
 To determine the mechanism of the different signaling by the D3 and D2 
dopamine receptors and their heterotrimeric G-proteins, I used fluorescence fluctuation 
spectroscopy (FFS) to study protein interactions. To label the receptors and 
heterotrimeric G-proteins, I used EGFP and mApple fluorescent protein. mCherry and 
mRFP had previously been used alongside EGFP in two-color, two-photon FFS studies; 
however, mApple had not. In my initial work, I characterized the mApple fluorescent 
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protein to confirm its utility for FFS studies. Due to the relation between fluorophore 
brightness and the signal-to-noise ratio in FFS, I hypothesized that mApple would be a 
superior choice for FFS studies. I showed the diffusion rates of mApple in solution and 
in the cell were comparable to previously reported fluorescent protein diffusion rates 
(134, 216–218). Furthermore, I showed a 2.5 fold increase in measured 
heteromerization between unlinked and linked EGFP and mApple control constructs. 
These experiments confirmed that mApple could be used to label proteins for single 
component FFS studies and be paired effectively with EGFP for two component studies. 
 Having established the utility of mApple in FFS experiments, I next measured the 
diffusion rates of the D3 dopamine receptor and Gγ subunit by FFS to establish both 
membrane proteins followed previously measured behavior for diffusion. I fit the 
measured autocorrelation curve with multiple diffusion models including single-
component, single-component with triplet fraction, and two-component. A two-
component model fit to the data yielded the smallest sum of least squares of the 
residuals.  Based on comparison with previous studies, I attributed the slower diffusion 
component represents the plasma membrane bound portion of the protein and the 
faster component represents the intracellular portion (176, 190, 193, 272).  I measured 
the diffusion rates before and after treatment with 100 µM of dopamine and found no 
statistically significant difference in diffusion rates before and after treatment. This 
finding is expected since the proteins are not internalized after treatment, but stay on 
the plasma membrane. Furthermore, the determined diffusion rates are in agreement 
with other reports for transmembrane and inner-leaflet proteins (194, 205–208). 
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 To test the hypothesis that the D3 dopamine receptor is activated after dopamine 
treatment, I measured the heteromerization between the D3 receptor and Gγ subunit in 
MIN6 cells. The Gβγ complex is a dimer of the Gβ and Gγ subunits, therefore I initially 
only labeled the Gγ subunit. I hypothesized I would measure a decrease 
heteromerization between the D3 receptor and Gγ subunit after dopamine treatment, 
indicating a ligand was bound to the D3 receptor and the heterotrimeric G-proteins were 
activated. However, my results showed very little heteromerization between the two 
proteins either before or after dopamine treatment.  
 We suspected that maybe both the Gγ and Gβ subunits needed to be 
overexpressed in order to detect signaling changes, so I simultaneously transfected a 
Gβ subunit labeled with mCerulean. mCerulean is not excited at the FFS excitation 
wavelength of 1000nm and therefore its presence does not interfere with two-color 
measurements with EGFP and mApple. I confirmed the presence and location of all 
three fluorescent proteins by spectral imaging.  Using this data, I could verify the 
localization of the Gβ and Gγ subunits and D3 dopamine receptor on the plasma 
membrane prior to FFS measurements. After overexpressing all three proteins, I 
measured a reduction in heteromerization between the D3 dopamine receptor and Gγ 
subunit indicating the D3 receptor was activated by dopamine. This result not only 
confirms the D3 receptor is activated after dopamine treatment, but also shows the 
requirement to express both subunits of the Gβγ complex to properly measure signaling 
by a G-protein coupled receptor (GPCR). 
 To determine whether the D2 receptor is similarly activated by dopamine, I 
overexpressed both the Gβ and Gγ subunits and D2 dopamine receptor in MIN6 cells. 
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Similar to the D3 receptor, I expected to observe a decrease in heteromerization 
between the D2 receptor and Gγ complex after dopamine treatment if the D2 receptor is 
activated. I found low heteromerization before and after treatment, indicating the D2 
receptor is not activated by dopamine during GSIS. This result agrees with a previous 
study which determined preferential signaling of D3 dopamine receptor over D2 
receptor to inhibit GSIS (120).  This result also agrees with previous studies which 
suggest the D2 receptor is localized to insulin granules (121, 221).  
 To investigate the proposed activation of GIRK in the dopamine mediated 
negative feedback pathway, I measured heteromerization interactions between GIRK3 
and the Gγ subunit. Because the GIRK channel is formed from the tetramerization of 
GIRK subunits, I chose to first measure interactions with the GIRK3 subunit due to its 
ability to form functional channels with all other subunits and thus testing a broad range 
of GIRK channels by labeling a single subunit (240, 244, 245).  Overexpressing the 
protein resulted in a large intracellular component. This was expected as the GIRK3 
subunit cannot form functional channels on its own. By overexpressing the protein, it 
appears that more GIRK3 subunits are formed than the cell can use in the production of 
GIRK channels. Single component measurements at the plasma membrane were 
performed to determine the plasma membrane diffusion rate. A two-component diffusion 
model gave the best fit, with the expected diffusion rates for membrane proteins, for the 
autocorrelation curves of GIRK3 (194, 205–208). Similar to what was found with the D3 
receptor and Gγ subunit measurements, no statistical difference was found in the 
diffusion rate of GIRK3 before and after dopamine treatment.  
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 To investigate whether D3 activation causes increased heteromerization between 
the Gβγ complex and GIRK channels, I performed FFS measurements between the Gγ 
subunit and GIRK3. I hypothesized that if a GIRK channel composed of the GIRK3 
subunit was activated by the Gβγ complex, I would measure an increase in 
heteromerization after dopamine stimulation between the Gγ subunit and GIRK3. FFS 
measurements showed no heteromerization between the two proteins either before or 
after dopamine stimulation. Measurements with both the Gβ and Gγ subunits present 
were not tested and are discussed further below in future experiments.  
 One explanation of the fast reaction of GPCR signaling is the close proximity of 
GPCRs and their downstream targets (267, 268). To test this theory with the dopamine 
receptor and GIRK channels, I sought to perform two-color FFS measurements 
between GIRK3 and the D3 dopamine receptor. If the two proteins are in a complex, I 
hypothesize they will have a heteromerization constant higher than two unlinked 
proteins. However, transfected cells that expressed both proteins exhibited cell rounding 
and improper membrane protein localization of the labeled proteins, suggesting that the 
cells are unhealthy. Therefore, no FFS measurements were performed between the D3 
dopamine receptor and GIRK channel.  
 Concurrent to taking two-color FFS measurements between the D3 dopamine 
receptor and the GIRK3 subunit, we hypothesized that improper trafficking of the GIRK3 
receptor might be occurring. Thus, I expressed the other 3 GIRK components with 
fluorescent tags into MIN6 cells independently. All GIRK subunits had large intracellular 
components, including the GIRK2 subunit which is able to form homotetramer GIRK 
channels (238, 239). Additionally, I co-expressed GIRK3 with GIRK2 and GIRK4 which 
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are both known to form functional GIRK channels with GIRK3. Unfortunately, none of 
these other transfections improved the plasma membrane localization. 
 
Future Directions 
Studying Interactions between DRD3 and GIRK Channel 
 I hypothesized activation of the dopamine receptor initiates the heterotrimeric G-
proteins to activate a GIRK channel which hyperpolarizes the membrane causing 
voltage gated calcium channels to close. This hypothesis was developed following 
results from unpublished patch-clamp studies by Dr. Jacobson and Dr. Ustione which 
showed that hyperpolarization of the membrane after dopamine stimulation results from 
potassium channel activation other than the KATP channel. Additionally, previous neural 
studies have shown activation of dopamine receptors signals to GIRK channels to open 
(265, 266, 273). However, the change in intracellular calcium could be due to direct 
inactivation of calcium channels by the Gβγ complex (274). If the Gβγ complex does 
inactivate calcium channels, no increase in heteromerization between labeled GIRK 
subunits and Gβγ complex would be observed after dopamine stimulation. The following 
proposed future studies which include the GIRK channel in this dissertation are based 
on the hypothesis that the Gβγ complex activates GIRK channels directly. 
 Above, I described the difficulties in measuring interactions between the GIRK 
channel and the DRD3 and Gβγ complex. To examine the potential interactions between 
the D3 receptor and GIRK channels, proper plasma membrane localization of GIRK 
subunits must first be achieved. First, I would determine which GIRK subunits 
tetramerize to form channels inherently in MIN6 β cells. I propose using western and 
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coimmunoprecipitation assays to detect interactions between subunits. These methods 
have been previously used to determine pairings of GIRK channels in neurons (241, 
242). After identifying which GIRK channels are formed in MIN6 β cells, specific pairs of 
GIRK subunits can be co-expressed in the cell to facilitate incorporation of these 
subunits in GIRK channels localized to the plasma membrane. For example, if GIRK1 
and GIRK2 channels are discovered to be most prominent in β cells, then GIRK1 and 
GIRK2 should be co-expressed for future experiments.  
 One possible explanation for improper plasma membrane trafficking of the GIRK 
subunits is the lack of conserved regions between the subunits due to the multiple 
species of origin: mouse, rat, and human. In oocytes, expression of subunits from 
different species has not inhibited the formation of functional channels at the plasma 
membrane, thus it was originally assumed this would also be the case for expression in 
MIN6 cells (259–261). Furthermore, the GIRK3 subunit tested here has not been 
previously paired to form functional channels with the other GIRK subunits tested (259–
261). The GIRK3 described in this dissertation could be improperly folding and therefore 
not interacting with other GIRK subunits properly, be they inherent to the cell or also 
transfected. Furthermore, the spacing between the turboGFP (tGFP) label and GIRK3 
could be interfering with the folding and trafficking of the GIRK3 subunit. To determine if 
this is the case, the mApple-GIRK3, which I constructed for measurements between the 
GIRK3 and D3 dopamine receptor, could be co-expressed with the other GIRK subunits 
previously shown to localize to the plasma membrane  (259–261). 
 To measure activation of the D3 receptor through the decreased 
heteromerizaiton of the receptor and heterotrimeric G-proteins, I had to overexpress 
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both the Gβ and Gγ subunits. In measuring interactions between the proposed 
downstream target, GIRK, and the Gβγ complex, which I hypothesize activates the GIRK 
channels, I only overexpressed GIRK3 and the Gγ subunit. It is reasonable to assume 
that expression of both the Gβ and Gγ subunits are necessary to properly measure 
signaling by the Gβγ complex to a downstream target.  
 Assuming GIRK is the downstream target signaled to by the Gβγ complex, 
activation of GIRK channels would result in hyperpolarization of the membrane which 
causes voltage gated calcium channels to close. For efficient signal transduction, all 
three proteins might be in close proximity on the membrane. It would be interesting to 
determine if voltage gated calcium channels and GIRK channels are located in close 
proximity to dopamine receptors. If all three proteins are determined to be in close 
proximity to each other, they could also be located with other GPCRs which control 
potassium and calcium channels in response to other stimuli in the β cell too (53, 72, 
103, 104). Alternatively, none of the three could be located in close proximity to each 
other since other stimuli control ion channel opening and closing also. A third potential 
outcome could be the close proximity of the downstream target protein, GIRK, and the 
D3 receptor, not proteins like the calcium channel involved in further downstream 
signaling. The relationship of all three proteins: D3 dopamine receptor, GIRK channel, 
and voltage gated calcium channel, can be measured between two proteins at a time 
through FFS.  I would begin measuring the heteromerization between the D3 receptor 
and GIRK channel. If the two are in close proximity to each other, I would then measure 
the heteromerization between the GIRK channel and voltage gated calcium channel. 
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Studying Interactions in Primary Cells 
 Many animal models have been used to study diabetes, for example, the D3 
receptor knock out mouse line. As a control experiment, signaling of receptor activation 
should be performed in primary β cells and the results compared to those reported in 
MIN6 cells. Primary cells from different animals can behave differently and therefore a 
broader range of results may occur in comparison to studies using cell lines. I 
performed initial primary cell studies by isolating islets from murine models, dispersing 
the cells, and then electroporating MIN6 cells with the D3 dopamine receptor and Gγ 
subunit constructs. Due to the fragility of primary cells, they cannot be electroporated 
with the same protocol as primary islets. I found reducing the voltage to 180V, for a 
single 5ms pulse resulted in the highest percentage of transfected cells. Also, 
harvesting islets is laborious and results in small amounts of cells. For efficient 
electroporations, a minimum cell mixture volume of 40µL at 108 cells/ml is required, 
usually requiring two murine pancreases for one electroporation cuvette. Thus, 
obtaining enough cells for efficient transfections will be difficult. Additionally, islets are 
composed of multiple cell types including α and δ cells which may exhibit different 
responses to dopamine. For murine primary cells, the majority of the islet is composed 
of β cells and thus statistically most measurements should be from β cells. Post study 
staining for insulin is one way to confirm measurements are only from β cells. However, 
this requires precise knowledge of exactly which cell each FFS measurement was taken 
from. 
 Having established the preference of signaling through the D3 receptor, it would 
be interesting to study the protein signaling pathway in the D3 knock out mouse line. 
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Unpublished data from Dr. Ustione shows islets lacking the D3 receptor secrete more 
insulin, but are still sensitive to dopamine. To further understand this occurrence, a two-
color FFS study between the D2 receptor and Gβγ complex in dispersed β cells from the 
D3 knock out mouse line could be performed. Additionally, this occurrence could be 
studied through the use of CRISPR or RNAi to knock-down the D3 receptor. It may be 
that the D2 receptor compensates for the long-term absolute lack of the D3 receptor. If 
this is the case, I would expect to observe a decrease in heteromerization between the 
D2 receptor and Gβγ complex after dopamine stimulation.  
Two Color SpIDA 
 Spatial intensity distribution analysis (SpIDA) allows protein interaction to be 
determined from raster images of cells by using spatial correlations between multiple 
pixels rather that temporal fluctuations from a single point measurement. The analysis 
measures changes in the fluorescent signal between pixels to determine a quantal 
brightness value of the fluorescent tag. A dimer would have twice the quantal brightness 
of a monomer. Two-color SpIDA is currently being developed and will determine protein 
heteromerization from cell images. It will be interesting to see if the same results from 
FFS are obtained from two-color SpIDA measurements. FFS requires a stable average 
fluorescence count to perform measurements and therefore slow moving proteins must 
be bleached before measurements. These proteins could be involved in signaling that is 
undetectable by FFS. For SpIDA measurements however, no bleaching occurs as 
differences in fluctuations are determined from changes in pixels. Furthermore, 
signaling by the Gβγ complex is difficult to measure by FFS due to its promiscuity with 
other GPCRs. Heteromerization between the Gβγ complex and the receptor or target 
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protein must be great enough to overcome the noise of other Gβγ complexes 
fluorescently labeled, but signaling in other pathways. SpIDA measures 
heteromerization only through histogram analysis of raster images and could measure 
interactions by the Gβγ complex graphically rather than over time as with FFS.  
 An advantage of SpIDA is that it can be performed on images taken of fixed cells. 
This is especially helpful in primary cells which are not as robust as cell lines and 
require staining for confirmation that measurements are performed on β cells and no 
other cell types in the islet. Thus, staining of βcells for insulin could be performed prior 
to heteromerization measurements so that β cells were easily distinguishable. While 
care must be taken to not alter protein localization or structure during fixation and 
staining, staining of endogenous protein would eliminate the potential toxicity of 
transfections which can alter cell functions.  
 Because it can be used on intrinsic proteins, two color SpIDA could be very 
advantageous to studying interactions with the GIRK channel. When overexpressing the 
GIRK plasmids, I showed lower plasma membrane localization than found when I 
overexpressed other membrane proteins. With SpIDA, dyes can be used to label the 
endogenous proteins of interest within the cell. Thus, endogenous GIRK channels could 
be fluorescently tagged by staining and their interactions with other proteins measured 
by two color SpIDA.  
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Significance 
 In this dissertation, I applied fluorescence fluctuation spectroscopy to study 
protein signaling at the cell membrane. Through changes in measured heteromerization 
between the D3 receptor and Gβγ complex, which were not found between the D2 
receptor and Gβγ complex, I confirmed the preferential signaling of the D3 receptor in 
the dopamine mediated feedback pathway. I showed the changes in heteromerization 
between a GPCR and heterotrimeric G-proteins during activation. Currently, 293 non-
odorant GPCRs have been found in islets, all of them signaling through heterotrimeric 
G-proteins (53). The G-proteins I overexpressed in the cell formed Gβγ complexes used 
in signaling other pathways. Thus, my data is significant because I was able to measure 
the changes in heteromerization between the D3 dopamine receptor over other 
signaling by Gβγ complexes occurring in the cell. Additionally, I used two fluctuation 
analysis methods, cross-correlation and brightness analysis, to confirm my results. This 
is the first time both methods have been used concurrently together to solve a biological 
problem.  
 The results of this dissertation are beneficial for creating treatments for patients 
developing type II diabetes. As a pre-diabetic patient’s insulin resistance increases, β 
cells compensate by increasing insulin secretion. The increased stress to produce more 
insulin leads to β cells death and hyperglycemia. Intervention to decrease insulin 
secretion at the time of insufficient regulation and production of insulin by β cells would 
prevent cell death. This dissertation work suggests only the stimulation of D3 receptors 
is necessary to decrease insulin secretion of the pancreas. 
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